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Resumo 
Para uma grande variedade de doenças ainda não existe um tratamento eficaz. 
Uma compreensão aprofundada dos mecanismos moleculares de doença e terapias 
específicas eficazes são ainda necessárias para várias doenças potencialmente fatais.  
Na última década os microRNAs foram descobertos como reguladores chave de 
milhares de genes a nível pós-transcricional tanto no estado fisiológico normal como em 
situação patológica. Estes pequenos RNAs não codificantes são altamente conservados 
entre os animais e a sua expressão inapropriada tem sido associada a várias doenças, tais 
como, cancros, doenças neurodegenerativas, autoimunes e cardiovasculares. Com base 
nestas observações, a terapia com miRNAs está a ser desenvolvida por várias 
companhias farmacêuticas com o objetivo de aumentar a resposta à doença e elevar as 
taxas de cura. As estratégias terapêuticas baseadas na modulação da expressão e função 
dos miRNAs, nomeadamente, o bloqueio e a restituição dos miRNAs foram estudadas 
nos últimos anos. Uma vez que os miRNAs atuam como moléculas-chave afetando 
diversos processos celulares através da regulação de diferentes genes, é expetável que as 
terapias com miRNAs sejam particularmente efetivas em doenças heterogéneas que não 
podem ser tratadas com um único agente terapêutico. No entanto, os efeitos fora do alvo 
são esperados como resultado da natureza pleiotrópica dos microRNAs.  
Apesar do fato de estarem a decorrer vários programas de descoberta de 
fármacos, o mais avançado desses programas está ainda em ensaio clínico de fase 2 para 
o tratamento da infeção pelo vírus da hepatite C. Um esforço adicional necessita de ser 
realizado para trazer essas abordagens terapêuticas baseadas em microRNAs para a 
prática clínica.  
 
Palavras-chave: microRNAs, silenciamento dos genes, doenças humanas, terapia 
baseada em miRNAs. 
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Abstract 
For a diverse range of diseases there are no effective treatments. A refined 
understanding of the underlying molecular mechanisms of disease and effective targeted 
therapies are still required for several life-threatening disorders. 
In the past decade, microRNAs have been discovered as master regulators of 
thousands of genes at the post-transcriptional level in both normal physiological 
conditions and in disease. These small non-coding RNAs are highly conserved among 
animals and their inappropriate expression has been linked to a variety of diseases, such 
as, cancer, neurodegenerative, autoimmune and cardiovascular diseases. Based on these 
remarks, miRNA-based therapies are being developed by several pharmaceutical 
companies with the principle to enhance disease response and elevate cure rates. 
Therapeutic strategies based on modulation of miRNA expression and function, namely, 
miRNA blocking and miRNA replacement therapies have been studied in recent years. 
Once, miRNAs act as key molecules affecting many cellular processes through the 
regulation of different genes, therapies based on miRNAs are expectable to be 
particularly effective in heterogeneous diseases tha t cannot be treated by a single 
therapeutic agent. However, off- target effects are expected as a result of pleiotropic 
nature of microRNAs. 
Despite the fact of many drug discovery programs are ongoing, the most 
advanced of these programs are yet in phase 2 clinical trials for the treatment of 
hepatitis C virus infection. An additional effort need to be made to bring these 
microRNA-based approaches to the clinic. 
 
Keywords: microRNAs, gene silencing, human diseases, miRNA-based therapies. 
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1. Historical introduction to microRNAs 
For several years geneticists have expected that human genome contained a 
greater number of protein-coding genes than simpler life forms, like Caenorhabditis 
elegans (Wright & Bruford, 2011). However, genomic sequencing has demonstrated 
that humans, mice and C. elegans share approximately an identical number of protein-
coding genes. This finding suggests that diversity of cell types and tissues found in 
complex organisms depends of the non-coding RNAs (ncRNAs) considered for many 
years as “junk” DNA (Costa, 2010; Taft, Pang, Mercer, Dinger, & Mattick, 2010). 
Currently there are mainly three types of small ncRNAs, to be exact, small-
interference RNAs (siRNAs), piwi- interacting RNAs (piRNAs) and microRNAs 
(miRNAs). During the last decade we have witnessed a near-exponential spread of 
scientific papers dedicated to regulatory RNAs as shown in Figure 1. All of these 
ncRNAs have the ability to target genes and silence their expression. Transcriptome 
analyses of small ncRNAs have brought to light new types of RNA molecules that do 
not fit into well-established classes (e.g. small nucleolar RNAs, snoRNAs) (Aalto & 
Pasquinelli, 2012).  
Figure 1 – Number of non-coding RNA publications during the last thirteen years. Records were 
retrieved using PubMed database. The search terms used were: siRNA, miRNA and piRNA. Note that 
2013 data were only collected until 20 October.  
 miRNAs are small silencing RNAs that regulate gene expression at the post-
transcriptional level affecting almost all cellular pathways, from development to 
oncogenesis (Ameres & Zamore, 2013). In mammals, miRNAs control approximately 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
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50% of all protein-coding genes and therefore disruption in their expression is linked 
with several human diseases (Krol, Loedige, & Filipowicz, 2010).  
In 1993, Victor Ambros a developmental biologist together with his co-workers 
Rosalind Lee and Rhonda Feinbaum described in Cell, the first miRNA in C. elegans, 
called lin-4. They found that lin-4 gene did not encode a protein but produced a pair of 
small transcripts that are complementary to 3´UTR region of lin-14 mRNA, which 
suggested an antisense regulatory mechanism (R. C. Lee, Feinbaum, & Ambros, 1993). 
In C. elegans nematode, the heterochronic genes lin-4, lin-14, lin-28 and lin-29 
control temporal postembryonic development, termed “larva-to-adult switch”. The 
switch is controlled by regulatory interactions between these genes, in the early stages 
lin-14 and lin-28 negatively regulate lin-29 and consequently prevent early switching, 
whereas in the later stage lin-4 inhibits lin-14 and lin-28 and activates lin-29 which 
promotes switching (Ambros, 1989). Why have scientists used the C. elegans over other 
animal models to study the regulation and function of miRNAs? Well, it is inexpensive 
to cultivate, easy to manipulate physically, transparent at every stage of their life cycle, 
has two sexes (hermaphrodite and male), their development cycle is clear and their 
larval development is rapid (Corsi, 2006; J. Liu, Yang, & Ai, 2013).     
Seven years after the discovery of the first miRNA, Reinhart et al. (2000) 
discovered the second miRNA in C. elegans. They demonstrated that let-7 is a 
heterochronic switch gene that contains a small RNA of ~21nt length, complementary 
to 3´UTR region of lin-14, lin-28, lin-41, lin-42 and daf-12 heterochronic genes. Let-7 
loss-of-function causes a return to larval cell fates during adult stage, whereas let-7 
gain-of- function causes precocious expression of adult fates during larval stage 
(Reinhart et al., 2000; Roush & Slack, 2008). Furthermore, lin-41 is negatively 
regulated by let-7 and negatively regulates lin-29 (Slack et al., 2000).  
Unlike lin-4, the 21-nt length of the let-7 RNA is highly conserved across animal 
species, indicating that this length is central to its function (Pasquinelli et al., 2000). 
This fact triggered a large-scale miRNA search and several new miRNAs in a wide 
range of animals have been identified (Lagos-Quintana, Rauhut, Lendeckel, & Tuschl, 
2001; Lau, Lim, Weinstein, & Bartel, 2001; R. C. Lee & Ambros, 2001). As of June 
2013 about 24521 hairpin sequences and 30424 mature miRNA sequences were 
published online at repository miRBase (Griffiths-Jones, 2013).  
1. Historical introduction to microRNAs  
17 
The first evidence for the involvement of miRNAs in human diseases was a 
discovery in 2002 of mutations in a region of chromosome 13 in two miRNAs with 
clinical importance in chronic lymphocytic leukemia (CLL). Since then, several 
diseases have been associated with miRNAs dysregulation and if we thought that the 
human genome contains hundreds of sequences of miRNAs that regulate thousands of 
protein-coding genes, then miRNAs are extremely important in human disease (de 
Planell-Saguer & Rodicio, 2011). 
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2. The microRNA biogenesis pathway 
The production of mammalian miRNAs begins with the transcription of one 
miRNA gene by RNA polymerase II (Pol II) or less frequently by RNA polymerase III 
(Pol III), to produce a capped and polyadenylated long primary miRNA transcript (pri-
miRNA) with a stem-loop structure (hairpin) which contains the mature miRNA 
sequence in the stem (Graves & Zeng, 2012). A typical pri-miRNA hairpin comprises 
an imperfect stem of ~33bp, a loop and flanking RNA segments at its base that are 
critical for processing (Han et al., 2006). 
There are two possible pathways of miRNA biogenesis, based on how the pri-
miRNAs are processed [Figure 2]. In the canonical pathway, the miRNA gene is 
localized in intergenic region and in the mirtron pathway, the miRNA gene is in the 
intron of a protein-coding gene (Graves & Zeng, 2012).  
In the canonical pathway, the pri-miRNA is cropped, in the nucleus, by the 
nuclear RNase III-type protein Drosha along with a cofactor DiGeorge syndrome 
critical region gene 8 (DGCR8) to form a truncated hairpin precursor-miRNA (pre-
miRNA) of ∼65 nt, which has 2-nt 3´ overhangs (Xiaoxiao Zhang & Zeng, 2010). The 
microprocessor complex that comprises Drosha and its cofactor, DGCR8, is crucial for 
pri-miRNA processing, which in turn is a critical step in miRNA biogenesis because it 
will define the mature miRNAs sequence (Han et al., 2006). The 6-11nt that flank a pri-
miRNA hairpin (5´or 3´ side) are unstructured by microprocessor complex at the 
distance ~11 bp from the ssRNA-dsRNA junction. An important consideration is that 
Drosha not cleave pri-miRNAs without its cofactor, DGCR8. Thus, RNA binding 
protein DGCR8 specifically recognizes the pri-miRNA and assists the cleavage by 
Drosha (Faller et al., 2010). 
Following nuclear processing, pre-miRNA is exported to the cytoplasm by 
Exportin 5 (EXP5) that binds cooperatively to its cargo and the GTP-bound form of the 
Ran cofactor in nucleus, and once in the cytoplasm releases the cargo and it is diced by 
another RNase III-type protein, Dicer, that produces a double-stranded miRNA duplex 
of ~22 bp, containing the guide strand (mature miRNA) and the passenger strand 
(miRNA*) (Xiaoxiao Zhang & Zeng, 2010). 
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Figure 2 – Schematic overview of miRNA biogenesis. (A) Canonical pathway of miRNA biogenesis  and 
mirtron biogenesis. (B) miRISC-mediated gene silencing. (Adapted from Bronevetsky & Ansel, 2013; 
Fabian & Sonenberg, 2012; Graves & Zeng, 2012; V. N. Kim, Han, & Siomi, 2009; Kro l et al., 2010; 
Westholm & Lai, 2011). 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
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The guide strand (or miRNA) is loaded into RNA-induced silencing complex 
(RISC), whereas the passenger strand is degraded. The guide strand is extremely 
important because it is responsible for translational inhibition and target destabilization 
of target mRNAs and is involved in several diseases when its expression is 
misregulated. But then, is the passenger strand always degraded or can it be a potential 
regulatory molecule? The miRNA* strand destiny depends on phylogenetic 
conservation. Well-conserved miRNA* strands can eventually play a significant roles in 
regulation network (L. Guo & Lu, 2010). Despite the mechanism of guide strand 
selection not being fully understood, it was suggested that the guanine–cytosine (GC) 
frequencies and pairing information of miRNA:miRNA* duplex are essential to the 
selection of guide strand (D. Ma et al., 2011).  
The core components of the miRNA-induced silencing complex (miRISC) is a 
miRNA-loaded into one of four Argonaute proteins (AGO1-4), which targets and 
silences the mRNAs in the 3´ untranslated regions (UTRs). There are other proteins, no 
less important, like PABP, CCR4-NOT and PAN2-PAN3 deadenylase complex linked 
to miRNA-mediated gene silencing (Fabian & Sonenberg, 2012). 
The specificity of miRNAs to mRNAs targets is determined by the sequence 
complementary between nucleotides 2-8 on the 5´end of the miRNA (“seed sequence”) 
and the 3´ unstranslated region (UTR) of the mRNA. There are three well studied 
mechanisms by which miRNAs regulate gene expression, namely, endonucleolytic 
cleavage, inhibition of translation initiation and mRNA degradation by deadenylation. 
When mRNA/miRNA match is perfect (or near perfect), the mechanism of gene 
silencing that occurs is through endonucleolytic cleavage of the scissile phosphate of 
the nucleotide paired to the 10th and 11th nucleotides of the guide RNA (Beezhold, 
Castranova, & Chen, 2010).  
In the mirtron pathway, an alternative miRNA biogenesis pathway, pre-miRNA 
generation happens by splicing of short introns with formation of a non linear spliced 
intron (excised intron). This spliced intron is a lariat in which the 3´ branchpoint is 
ligated to the 5´ end of the intron and it is subsequently linearized by lariat debranching 
enzyme (Ldbr) (Westholm & Lai, 2011).  
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In the last years, the biochemical and functional properties of mirtrons have been 
studied in D. melanogaster, C. elegans and vertebrates. There are three classes of 
splicing-derived miRNAs in mammals, to be precise, conventional mirtrons, 5´-tailed 
mirtrons and 3´-tailed mirtrons. In conventional mirtrons biogenesis, splicing and 
debranching defines both ends of pre-miRNA hairpin, whereas "tailed" mirtrons contain 
unstructured extensions at their 5´ tails (5´-tailed mirtrons) and 3´ tail (3´-tailed 
mirtrons). 3´-tails exists in Drosophila and are trimmed by RNA exosome, whilst 
vertebrate 5´-tails are trimmed by an enzyme not yet discovered (Ladewig, Okamura, 
Flynt, Westholm, & Lai, 2012). 
Mirtrons do not require the microprocessor complex for miRNA processing 
because spliceosome-excised introns are diced directly. Recently, it was discovered that 
some miRNAs are not processed by the canonical miRNA pathway neither mirtron-
processing pathway, so-called "simtrons". The biogenesis of these new regulatory 
molecules, for example miR-1225 and miR-1228, does not require DGCR8, Dicer or 
EXP-5, but is capable of gene silencing (Havens, Reich, Duelli, & Hastings, 2012). 
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3. microRNAs and cancer 
3.1. microRNAs as oncogenes or tumor suppressors 
The abnormal expression of miRNAs is implicated in human tumorigenesis. The 
upregulation of oncogenic miRNAs (oncomiRs) leads to tumor develop ment by 
negatively targeting tumor suppressor proteins or proteins that control cell 
differentiation and apoptosis. On the other hand, the downregulation of tumor 
suppressive miRNAs (tsmiRs) leads to tumor development by upregulation of 
oncogenic proteins [Figure 3] (Ahmad et al., 2013). 
A single miRNA has the ability to regulate multiple targets, so the function of 
miRNAs are also wide-ranging, including regulation of cancer stem cell properties, 
tumor proliferation, apoptosis, invasion and angiogenesis (Mizoguchi et al., 2013). 
 
Figure 3 – miRNAs function as oncogenes or tumor suppressors in cancer cells. (a) Upregulation (gain of 
function) of oncogenic miRNAs reduces expression of tumor suppressor protein. (b) Downregulation 
(loss of function) of tumor suppressor miRNA results in an increased production of oncogenic protein.  
(Adapted from Mizoguchi et al., 2013; Nohata, Hanazawa, Kinoshita, Okamoto, & Seki, 2013). 
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Growing number of tsmiRs and oncomiRs are being involved in different types 
of human cancers. Some of the most usually dysregulated miRNAs are summarized in 
Table 1.  
Table 1 – Some miRNAs involved in d iverse human cancers with altered expression levels . 
Cancer type tsmiR(s) oncomiR(s) Reference(s) 
Breast cancer 
miR-497 
miR-125b  
miR-485 
miR-15a 
miR-510 
(Luo, Li, Gao, et al., 2013), (Feliciano et al., 2013), 
(Anaya-Ruiz, Bandala, & Pérez-Santos, 2013), 
(Luo, Li, Li, et al., 2013), (Q. J. Guo et al., 2013). 
Pancreatic cancer miR-141 miR-27a 
(G. Zhao et al., 2013), (Y. Ma, Yu, Zhao, Lu, & 
Chen, 2010). 
Gastric cancer miR-202-3p 
miR-363 
miR-181a 
(Y. Zhao et al., 2013), (Hsu et al., 2013), 
(Xiangyang Zhang et al., 2012). 
Human glioma miR-106a 
miR-223 
miR-372 
(Dai et al., 2013), (B.-S. Huang et al., 2013), (G. Li 
et al., 2013). 
Prostate cancer miR-145 
miR-125b  
miR-21 
(Amir et al., 2013), (Reis et al., 2012), (Avgeris, 
Stravodimos, Fragoulis, & Scorilas, 2013) 
Bladder cancer miR-23b miR-182-5p (Shahana Majid et al., 2013), (Hirata et al., 2012). 
NPC miR-138 miR-18b (Yu et al., 2013), (X. Liu et al., 2012). 
LSCC miR-370 miR-21 
(Yungang, Xiaoyu, Pang, Wenming, & Pan, 2013) , 
(Ren, Zhu, Liu, Sun, & Tian, 2010). 
OSCC miR-145 miR-155 
(Shao, Qu, Dang, Yao, & Ji, 2013), (Rather, 
Nagashri, Swamy, Gopinath, & Kumar, 2013). 
CRC 
miR-124 
miR-133a 
miR-339-5p 
miR-31 
miR-130a 
miR-301a 
miR-454 
(J. Zhang et al., 2013), (Zhou et al., 2013), (Dong et 
al., 2013), (D. Sun et al., 2013), (L. Liu et al., 2013). 
ESCC miR-195 miR-34b (Fu et al., 2013), (Harata et al., 2010). 
HCC 
miR-29c 
miR-503 
miR-224 
(Bae et al., 2013), (Xiao et al., 2013), (Donglaima, 
Tao, Gao, Fan, & Wu, 2012). 
NSCLC miR-16 miR-135b  (Ke, Zhao, Xiong, & Cao, 2013), (Lin et al., 2013). 
PDA  miR-217 miR-21 
(Sicard, Gayral, Lu lka, Buscail, & Cordelier, 2013), 
(W.-G. Zhao et al., 2010). 
Abbreviations: NPC, nasopharyngeal carcinoma; LSCC, laryngeal squamous cell carcinoma; OSCC, oral 
squamous cell carcinoma; CRC, colorectal cancer; ESCC, esophageal squamous cell carcinoma; HCC, 
hepatocellular carcinoma; NSCLC, non-small cell lung carcinoma; PDA, pancreatic ductal 
adenocarcinoma. 
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3.2. microRNAs targeting the hallmarks of cancer 
Human tumorigenesis is a multistep process that reflects changes in gene 
expression. In the year 2000, the cancer researchers Douglas Hanahan and Robert 
Weinberg published “The Hallmarks of Cancer”, that comprises six biological abilities 
acquired by cancer cells during the multistep development of human tumours (Hanahan 
& Weinberg, 2000). Two years ago, Weinberg and Hanahan proposed four new 
hallmarks as a result of scientific progress in the last decade. Actually, there are ten 
hallmarks that drive the transformation of normal cells to cancer cells, including, 
sustaining proliferative signaling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis, evading apoptosis, 
deregulating cellular energetics, genome instability and mutation, avoiding immune 
destruction and tumour-promoting inflammation (Hanahan & Weinberg, 2011). This 
work focused on the role of miRNAs in the hallmarks of human cancers as described by 
Hanahan and Weinberg [Figure 4].  
 
 
 
 
Figure 4 – The role of miRNAs in the hallmarks of human cancers. (Adapted from Bala et al., 2012; 
Chou et al., 2013; Creevey et al., 2013; Dar et al., 2011; Fei et al., 2012; He et al., 2013; Q. Huang et al., 
2013; J. S. Kim et al., 2013; S. Lee et al., 2011; Menghini et al., 2009; Nachmani, Stern -Ginossar, Sarid, 
& Mandelboim, 2009a; Sh iiba et al., 2013; Shirasaki et al., 2013; C. -Y. Sun et al., 2013; Y. Wang et al., 
2011; C.-D. Wu, Kuo, Wu, & Lin, 2011; C.-W. Wu et al., 2013; Y. Xie et al., 2013; Y.-F. Xie et al., 
2013a; Yang et al., 2013). 
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3.2.1. microRNAs regulate immune responses in cancer 
The immune system is crucial to prevent tumor formation and progression, 
however, cancer cells have developed the faculty to escape the immune surveillance and 
proliferate. miRNAs are key mediators in immune system development and function in 
innate and adaptive immune responses. Dysregulation of these regulatory molecules can 
activate the occurrence of cancers in the immune system (Davidson-Moncada, 
Papavasiliou, & Tam, 2010). 
The infectious agents, Epstein-Barr virus (EBV/human herpesvirus 4) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV/human herpesvirus 8) are well known 
oncogenic viruses. They are mainly linked to lymphoproliferative diseases and 
lymphomas that occur in persons with HIV/AIDS or in those with iatrogenic 
immunodeficiency (IID) following solid organ transplantation (Carbone, Cesarman, 
Spina, Gloghini, & Schulz, 2009). A recent study shows that KSHV and EBV have 
functionally conserved miRNAs, respectively miR-K12-7 and miR-BART-5p, that 
downregulate MICB to avoid immune cell attack by natural killer (NK) cells 
(Nachmani, Stern-Ginossar, Sarid, & Mandelboim, 2009b). Human NK cells are innate 
immune lymphocytes that recognize abnormal cells, to be precise, tumor and virus-
infected cells. NK cells are activated when stress-induced ligands (e.g. MICB) are 
expressed on the surface of abnormal cells and are recognized by activating NK cells 
receptors, like NKG2D. MiRNAs plays an important role in NK cell regulation and 
consequently in hematopoietic system (Leong, Sullivan, & Fehniger, 2012).  
Beyond KSHV and EBV, other oncoviruses express miRNAs that have the 
ability to protect the virus from immune surveillance. Merkel cell carcinoma (MCC), 
discovered in 1972 by Cyril Toker, is an aggressive neuroendocrine tumor caused, at 
least in 80% of cases, through Merkel cell polyomavirus (MCV). This virus becomes 
part of normal human flora, establishing an asymptomatic infection, however, mutations 
in the large T-antigen (LT) and dysfunction of the host´s immune system (e.g. 
individuals with CLL or IID) contribute to development of tumor cells (Amber, 
McLeod, & Nouri, 2013). MCV expresses a miRNA, MCV-miR-M1-5p, late in 
infection and thereby suppresses viral LT, most likely to protect the virus from immune 
surveillance. However, MCV-miR-M1-5p is expressed at low levels because some LT 
expression is essential for MCC expansion (S. Lee et al., 2011). 
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3.2.2. microRNAs control angiogenesis in cancer 
Angiogenesis is a physiologic process that contributes to the formation of new 
blood vessels from pre-existing vasculature. In cancer cells, this process is accelerated 
because the overproduction or induction of pro-angiogenic factors in tumor 
microenvironment, such as, vascular endothelial growth factor (VEGF). Thus, in bone 
marrow (BM) deregulated angiogenesis is linked to disease progression and poor 
prognosis in multiple myeloma (MM) patients (Giuliani, Storti, Bolzoni, Palma, & 
Bonomini, 2011). 
MM is a cancer of plasma B cells characterized by clonal proliferation of 
malignant plasma cells in the bone marrow microenvironment and extramedullary sites 
(e.g. cortical bone). The pathogenesis of MM results from a cascade of several genetic 
and microenvironmental events starting with monoclonal gammopathy of undetermined 
clinical significance (MGUS), followed by smoldering myeloma and ends with 
symptomatic myeloma. Current treatment for patients with MM has include autologous 
stem-cell transplantation and use of thalidomide, lenalidomide and bortezomib  
(Laubach, Richardson, & Anderson, 2011; Palumbo & Anderson, 2011). 
Sun et al. (2013) recently discovered that miR-15a and miR-16 are down-
regulated in ~70% of MM tumors, especially in advanced stage tumors, suggesting that 
downregulation of these miRNAs contributes to disease progression. This study found 
that both miRNAs are complementary to the VEGF-A 3´-UTR and that this interaction 
inhibits the overexpression of VEGF in MM cells. Thus, restoration of normal 
expression miR-15a and miR-16 can improve prognosis of MM patients by modulation 
of angiogenesis through targeting VEGF-A (C.-Y. Sun et al., 2013). This study is proof-
of concept that miRNAs regulate the angiogenic process in cancer and that miRNAs 
could be used as an anti-angiogenic treatment therapeutic approach. 
Another recent study has demonstrated the role of miRNAs in the regulation of 
angiogenesis in cancer. Epithelial ovarian cancer (EOC) is a large group of tumors  
responsible for the majority of lethal gynecologic malignancies (A. Kim, Ueda, Naka, & 
Enomoto, 2012). Recent findings showed that miR-199a and miR-125b have anti-
angiogenic properties in ovarian cancer tissues. When overexpressed, these miRNAs 
downregulate hypoxia- inducible factor 1 alpha (HIF-1α) protein expression and VEGF 
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mRNA levels, showing that both miRNAs are inhibitors of tumor angiogenesis (He et 
al., 2013). 
3.2.3. microRNAs regulate inflammation in cancer 
Recent data reveal that some miRNAs are capable of regulating the 
inflammatory response in cancer, for example, in orodigestive periodontitis-related 
cancer. Periodontitis is an inflammatory disease that affects the oral periodontium, the 
set of tissues that support the teeth. This disease is the most common cause of tooth loss 
and several bacterial species are involved, namely, Porphyromonas gingivalis, 
Tannerella forsythia and Treponema denticola (Darveau, 2010). Orodigestive cancer 
mortality is linked to periodontitis and P. gingivalis orodigestive colonization (Ahn, 
Segers, & Hayes, 2012). 
Recent data suggest that miR-146a and miR-146b-5p are up-regulated in 
periodontal disease and consequently decrease pro- inflammatory cytokines (e.g. IL-1β, 
IL-6 and TNF-α) by inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) 
expression through direct binding to the 3´-UTR of IRAK1. Therefore, miR-146 is a 
negative regulator of immune response in periodontal inflammation (Y.-F. Xie et al., 
2013b).  
Other current study has exposed that miR-155 upregulation in monocytes of 
patients with hepatitis C virus (HCV) infection increases pro- inflammatory state and 
also suggests the possibility of use miR-155 as disease biomarker (Bala et al., 2012). 
3.2.4. microRNAs target growth suppressors in cancer 
miRNAs by targeting tumor suppressors (TS) or regulators of cell cycle might 
promote or inhibit tumor growth. A recent study has demonstrated that miR-205 is 
under-expressed in oral cancer cells comparatively to human normal oral keratinocytes. 
This study also showed that miR-205 over-expression in human KB oral cancer cells 
upregulates a tumor suppressor, the interleukin-24 (IL-24), by targeting their own 
promoter binding site. This causes increased cell toxicity and apoptosis by activation of 
caspase-3/-7 and represents an achievable therapeutic treatment for oral cancer (J. S. 
Kim et al., 2013).  
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Another study has demonstrated the role of miRNAs in growth/proliferation of 
paediatric brain cancer. Neuroblastoma is a pediatric tumor of the autonomic nervous 
system, affects ~10 children per million births and is the leading cause of cancer during 
the first year of life (Maris, 2010). miR-497 over-expression triggers the apoptosis in v-
myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN)-
amplified neuroblastoma cells by targeting the 3´-UTR of WEE1, a tyrosine kinase 
regulator of the cell cycle. This finding suggests that WEE1 can be a therapeutic target 
in neuroblastoma management (Creevey et al., 2013).  
3.2.5. microRNAs regulate tissue invasion and metastasis 
miRNAs have the ability to regulate metastatic potential of tumors and the 
outcomes among patients, particularly, in breast cancer and cholangiocarcinoma (CCA).  
In breast cancer, GATA 3 is a transcription factor (TF) that regulates epithelial 
cell differentiation in mammary gland and suppresses breast metastasis. GATA 3 gene 
is mutated in more than 10% of all breast cancers and the loss of GATA 3 expression is 
predictive of poor prognosis. This TF induces anti-metastatic miR-29b expression that 
inhibits metastasis by targeting a network of pro-metastatic regulators, such as, 
ANGPTL4, LOX and MMP9. This discovery, based on GATA3-miR-29b axis, brings a 
new therapeutic field to the treatment of breast cancer patients (Chou et al., 2013). 
CCA is the most frequent biliary tract cancer characterized by being difficult to 
diagnose and classified into intrahepatic, perihilar and distal extrahepatic CCA 
(Blechacz, Komuta, Roskams, & Gores, 2011). It’s known that miR-21 is overexpressed 
in CCA cells. A recent study demonstrates that knockdown of miR-21 inhibit cellular 
invasion and metastasis and increases reversion- inducing-cysteine-rich protein with 
kazal motifs (RECK) protein levels. MiR-21 targets RECK, a metastasis suppressor 
gene, and promote cell invasion and metastasis (Q. Huang et al., 2013).      
3.2.6. microRNAs control cellular metabolism 
Metabolism is a set of chemical reactions essential for development, growth and 
survival of any living organism. Metabolic stimuli (e.g. nutrients, hormones and 
cytokines) induces miRNA biogenesis/expression which, in turn, regulate metabolism 
homeostasis or lead to metabolic diseases (Dumortier, Hinault, & Van Obberghen, 
2013). miRNAs controls cancer cell metabolism by regulating several biological 
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processes, such as, glucose uptake, glycolysis, tricarboxylic acid cycle, insulin 
production, lipid metabolism and amino acid biogenesis (B. Chen et al., 2012). Here, I 
will explain the regulation of cellular metabolism by miRNAs in human bladder cancer 
and in HCV infection. 
Bladder cancer is the most common malignancy of the urinary tract, however, 
the mortality rates have declined in recent years, probably due to improved diagnostic 
techniques and therapeutics (Cheung, Sahai, Billia, Dasgupta, & Khan, 2013). The main 
risk factors for bladder cancer include genetic and molecular abnormalities (e.g. 
oncogene activation and tumor suppressor gene inactivation), chemical and 
environmental exposures (e.g. cigarette smoking) and chronic irritation in patients with 
bladder catheters (e.g. Schistosoma haematobium infestation) (Kaufman, Shipley, & 
Feldman, 2009). 
Glucose transport in bladder cancer is increased, due to upregulation of the high 
affinity glucose transporter member 3 (GLUT3). Fei et al. (2012) have for the first time 
discovered that miR-195-5p over-expression downregulates the GLUT3 protein level in 
bladder cancer. This finding suggests that miR-195-5p could function as a tumor 
suppressor in bladder cancer. Although, miR-195-5p expression is up-regulated in 
Chronic lymphocytic leukemia (CLL), meaning that this miRNA can play different 
roles in various cancers (Fei et al., 2012).    
HCV infection is a major health problem that can lead to cirrhosis and 
hepatocellular carcinoma (HCC) several years after the initial asymptomatic infection 
(Pécheur, 2012). The process that mediates HCV cell entry, replication and initiation of 
infection involves a range of molecules, namely, lipoproteins (Burlone & Budkowska, 
2009). A recent study showed that miR-27a overexpression decreased viral infectivity 
through the repression of lipid metabolism-related genes (e.g. Apoliprotein B100) 
which plays a crucial role in the production of new viral particles. Another important 
finding is that miR-27a is upregulated in HCV infection (Shirasaki et al., 2013). Is it 
possible that overexpression of miR-27a contributes to the progression of the disease? 
Shirasaki et al. (2013) argue that miR-27a overexpression maintains a low viral load by 
conferring to the virus the ability to escape immune detection and causes chronic HCV 
infection (Shirasaki et al., 2013). 
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3.2.7.  microRNAs regulate the limitless replicative potential of cancer cells 
Senescence and immortality are two physiological processes that control the 
replicative potential of cells. Senescence is a tumor suppression mechanism that occurs 
in response to cell stress (e.g. telomere dysfunction), whereas, immortality is the ability 
to escape senescence (Y. Kong, Cui, Ramkumar, & Zhang, 2011). Recently, it was 
discovered that some miRNAs have the ability to regulate the limitless replicative 
potential of melanoma and endothelial cells. 
The transcription factor E2F1, a master regulator of the G1/S cell cycle transition 
phase, when overexpressed, it triggers an oncogenic event that enhances the 
proliferation of melanoma cells. Dar et al. (2011) have demonstrated that 
overexpression of miR-205 in melanoma cells reduced E2F1 protein levels and, in turn, 
induced a senescent phenotype (Dar et al., 2011). 
The atherosclerosis and coronary artery disease are age related diseases. The 
Silent information regulator 1 (SirT1) is an important regulator that promotes longevity 
and prevents disease by avoiding stress- induced senescence. miR-217 is gradually 
expressed in endothelial cells during aging and is a natural inhibitor of SirT1 during 
endothelial senescence. This fact opens a new opportunity to prevent endothelial 
dysfunction in metabolic diseases (Menghini et al., 2009). 
3.2.8.  microRNAs control genomic instability of cancer cells 
Several studies have confirmed the role of miRNAs in the regulation of genomic 
instability in cancer cells (e.g. colon cancer). Ataxia Telangiectasia Mutated (ATM) 
protein is responsible for the repair of double-strand DNA breaks (DSB), an extremely 
cytotoxic DNA lesion. miR-18a is upregulated in human colorectal cancer (CRC) and 
negatively regulates ATM by targeting ATM 3´UTR. Thus, miR-18a has an oncogenic 
role in CRC through the attenuation of cellular repair (C.-W. Wu et al., 2013). 
Histone H2AX is involved in DNA damage response and repair by forming a 
large nuclear domain (foci) after double-strand DNA breakage. Wang et al. (2011) have 
discovered that miR-138 binds to H2AX 3´UTR and promotes chromosomal instability 
after DNA damage and sensitized cells to DNA-damaging agents (e.g. cisplatin, 
camptothecin and ionizing radiation). This discovery makes miR-138 a promising 
3. microRNAs and cancer  
31 
therapeutic agent in improving the efficacy of radiotherapy and chemotherapy in cancer 
patients (Y. Wang et al., 2011). 
3.2.9. microRNAs regulate apoptosis in cancer 
Apoptosis is programmed cell death that occurs in physiological and 
pathological situations and is characterized by a loss of equilibrium among cell division 
and the cell death (Wong, 2011). Various miRNAs participate in the apoptotic signaling 
pathway. 
The hormone Prothymosin-alpha (PTMA) is an apoptotic inhibitor that binds to 
apoptotic protease activating factor 1 (Apaf-1). A recent study has suggested that miR-1 
induces nasopharyngeal carcinoma apoptosis by targeting PTMA mRNA (C.-D. Wu et 
al., 2011). 
The caspase inhibitor, X- linked inhibitor of apoptosis protein (XIAP), has a 
crucial role in stopping apoptotic cell death. Recently it was demonstrated that miR-24 
downregulates XIAP expression by targeting 3´UTR of the XIAP mRNA. This 
discovery can possibly overcoming the apoptosis resistance problem in cancer cells (Y. 
Xie et al., 2013). 
3.2.10.  microRNAs regulate uncontrolled proliferation in cancer cells 
Current studies have proven that miRNAs have the ability to control the 
uncontrolled proliferation in different cancers, such as, gastric cancer and oral 
squamous cell carcinoma (OSCC). 
Gastric cancer is the second cause of death worldwide, normally, it is diagnosed 
in advanced stages of disease and an early diagnostic is crucial for good prognosis 
(Takahashi, Saikawa, & Kitagawa, 2013). Phosphatase and tensin homolog (PTEN) acts 
as a tumor suppressor gene in human gastric cancer, however, its expression is 
decreased in gastric cancer cells. miR-214 is overexpressed in gastric cancer and 
negatively regulates PTEN. Knockdown of miR-214 inhibits proliferation of gastric 
cancer cells and improves the prognosis (Yang et al., 2013). 
Intercellular adhesion molecule 2 (ICAM2) plays a crucial role in OSCC 
radioresistance. MiR-125b negatively regulates ICAM2 and by that way increases 
radiosensitivity. Furthermore, OSSC-derived cells have a lower proliferation rate when 
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miR-125b is expressed. These results propose that miR-125b suppress cell proliferation 
and overcomes the radioresistance problem in OSCC (Shiiba et al., 2013). 
The following Table 2 describes summarily several miRNAs and its predicted 
targets. 
Table 2 – miRNA and the hallmarks of cancer 
Hallmarks of cancer Target (s) miRNA (s) Reference 
Avoiding immune 
destruction 
Host MICB 
miR-BART-5p  
miR-K12-7 
(Nachmani et al., 2009b) 
MCPyV large T-
antigen 
MCV-miR-M1-5p  (S. Lee et al., 2011) 
Inducing angiogenesis 
VEGF  
miR-15a 
miR-16 
(C.-Y. Sun et al., 2013) 
VEGF / HIF-1α  
miR-199a 
miR-125b  
(He et al., 2013) 
Tumour-promoting 
inflammation 
IRAK 1 
miR-146a 
miR-146b-5p  
(Y.-F. Xie et al., 2013b) 
TNFα  miR-155 (Bala et al., 2012) 
Evading growth 
suppressors 
IL-24 promoter miR-205 (J. S. Kim et al., 2013) 
WEE1 miR-497 (Creevey et al., 2013) 
Activating invasion and 
metastasis 
ANGPTL4  
LOX / MMP9 
miR-29b (Chou et al., 2013) 
RECK miR-21 (Q. Huang et al., 2013) 
Deregulating cellular 
metabolism 
GLUT3 miR-195-5p (Fei et al., 2012) 
ApoB100 and others miR-27a (Shirasaki et al., 2013) 
Unlimited replicative 
potential 
E2F1 miR-205 (Dar et al., 2011) 
SirT1 miR-217 (Menghini et al., 2009) 
Genome instability and 
mutation 
ATM miR-18a (C.-W. Wu et al., 2013) 
H2AX miR-138 (Y. Wang et al., 2011) 
Evading apoptosis 
PTMA miR-1 (C.-D. Wu et al., 2011) 
XIAP miR-24 (Y. Xie et al., 2013) 
Sustaining proliferative 
signaling 
PTEN miR-214 (Yang et al., 2013) 
ICAM2 miR-125b  (Shiiba et al., 2013) 
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4. microRNAs and neurodegenerative diseases 
Aging is one of the major factors that contribute to brain neurodegeneration. In a 
current Letter published in Nature, Liu et al. (2012) demonstrate that miR-34 is 
involved is age-associated diseases and long-term brain integrity in Drosophila. Thus, 
miR-34 upregulation suppresses neurodegeneration and extends lifespan, whereas, miR-
34 downregulation triggers brain aging and late-onset degeneration (Nan Liu et al., 
2012). 
Recent studies showed that some miRNAs from patients with neurodegenerative 
diseases (NDs) are deregulated in the brain. For example, disruption of proteins 
required for miRNA biogenesis (e.g. loss of Dicer) induces neurodegeneration (Abe & 
Bonini, 2013). Several studies have proved that miRNAs are differentially expressed in 
subtypes of neurons and also regulate genes involved in NDs (Junn & Mouradian, 
2010).  
NDs are progressive disorders that include Alzheimer´s disease (AD), 
Parkinson´s disease (PD), Amyotrophic lateral sclerosis (ALS), Huntington´s disease 
(HD) and Spinocerebellar ataxias (SCAs) (Abe & Bonini, 2013). All of these diseases 
share a common feature, protein aggregates in different brain regions. The accumulation 
and aggregation of misfolded proteins in the brain leads to neuronal dysfunction and 
accelerates neurodegeneration (S.-J. Lee, Lim, Masliah, & Lee, 2011). Here will be 
discussed examples of scientific experiments displaying the role of miRNAs in 
neurodegenerative diseases.  
4.1. Alzheimer´ s Disease 
AD is a neurologic illness characterized by continuous loss of neurons and 
consequently cognitive functions (e.g. memory) (Y. Huang & Mucke, 2012). 
Accumulation of β-amyloid (Aβ) peptide and abnormal filaments of Tau in brain 
establishes the disease. Despite progress with anti-amyloid strategies this disease 
remains incurable and leads to death ~9 years after AD diagnosis (Citron, 2010). 
The abnormal expression of several miRNAs in hippocampus and cerebrospina l 
fluid (CSF) of AD patients is correlated with AD development (Müller, Kuiperij, 
Claassen, Küsters, & Verbeek, 2013). Zhu et. al (2012) have studied the role of miR-
MicroRNAs in pathology and as therapeutic targets in gene therapy 
34 
195 in the central neural system and found that miR-195 negatively regulates 
Beta-secretase 1 (BACE1) mRNA translation and consequently inhibits Aβ formation in 
vitro [Figure 5] (H.-C. Zhu et al., 2012). On the other hand, in vivo studies have 
strengthened the role of miRNAs in Aβ plaque formation. In a recent study, miR-153 
downregulated amyloid precursor protein (APP) [Figure 5] and its ortholog amyloid 
precursor- like protein 2 (APLP2) in transgenic mouse model, suggesting miR-153 is a 
potential target in AD therapeutic management (Liang et al., 2012). 
 
 
 
 
 
 
 
 
Figure 5 – miRNA targeting amyloid pathway in Alzheimer´s Disease. (Adapted from Holohan, Lahin, 
Schneider, Foroud, & Saykin, 2013). 
4.2. Parkinson´s disease 
Parkinson´s disease is a degenerative disorder of the central nervous system 
marked by death of dopaminergic neurons in substantia nigra, gliosis and the presence 
of eosinophilic intracytoplasmic inclusions, called Lewy bodies. These inclusions are 
abnormal aggregates of neuronal proteins, mainly alpha-synuclein (Margis, Margis, & 
Rieder, 2011). 
Several gene mutations are implicated in monogenic PD, namely, SNCA, 
PARK2, PINK1, PARK7 and LRRK2 mutations (Filatova, Alieva, Shadrina, & 
Slominsky, 2012). In particular, LRRK2 missense mutations are linked to PD onset. A 
current study has showed that LRRK2 protein expression is increased in PD human 
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brains, however, miR-205 expression is decreased. miR-205 has the ability to 
target directly the 3´-UTR mRNA of LRRK2 gene and therefore suppresses its 
expression. Researchers propose that miR-205 has a therapeutic potential in PD and also 
as biomarker of the disease (Cho et al., 2012). 
Alpha-synuclein oligomers are mediators of neurodegeneration in PD, as they 
confer toxicity to cells and initiate neuronal death (Kalia, Kalia, McLean, Lozano, & 
Lang, 2013). A recent study demonstrated that two miRNAs widely expressed in the 
brain, miR-7 and miR-153, bind directly to the 3´-UTR α-synuclein mRNA and repress 
α-synuclein expression. Lowering endogenous α-synuclein levels may represent an 
interesting approach for PD therapy (Doxakis, 2010). 
4.3. Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis, also called motor neurone disease, is a 
neurodegenerative disorder of the motor neurons in brainstem, spinal cord and motor 
cortex. This illness can be grouped in familial ALS (fALS) or sporadic ALS (sALS).  
The main signs and symptoms are muscle atrophy, weakness, fasciculations and muscle 
spasticity that usually appear after 40 years of age. Proteins associated with ALS, such 
as, TAR DNA-binding protein 43 (TDP43) and RNA-binding protein FUS are involved 
in pre-mRNA splicing, RNA transport and RNA translation, suggesting that abnormal 
RNA metabolism may be crucial to the ALS pathogenesis (Robberecht & Philips, 
2013). 
Williams et al. (2009) showed that expressing miR-206, a skeletal muscle-
specific miRNA, promotes nerve regeneration in ALS mouse model after acute nerve 
damage. This finding brings a potential target for ALS therapy (Williams et al., 2009). 
Another study demonstrated that miR-9 negatively regulates the neurofilament heavy 
subunit (NF-H) mRNA in spinal motor neurons. This neurofilament was previously 
implicated in ALS and thereby miRNA-mediated NF-H downregulation could slow or 
reverse neurodegenerative states (Haramati et al., 2010). 
4.4.  Huntington´s disease 
Huntington´s disease is a progressive, fatal, neurodegenerative genetic disorder 
marked by progressive motor dysfunction, psychiatric disturbances, dementia and 
weight loss. The HD gene encodes to huntingtin (Htt), an abundantly expressed protein 
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in human body. Mutation in HD gene originates an expanded CAG-triplet repeat, which 
encodes polyglutamines (PolyQs) within Htt protein that results in neuropathologic 
changes in neostriatum and cerebral cortex. Tetrabenazine is the only approved drug for 
HD, so it is imperative to find new therapeutic approaches (Krobitsch & Kazantsev, 
2011; Ross & Tabrizi, 2011). 
A current study has demonstrated that miR-22 overexpression is potentially 
neuroprotective using in vitro models of HD. miR-22 has the ability to target several 
genes linked to HD, such as, histone deacetylase 4 (HDAC4), REST corepresor 1 
(Rcor1) and regulator of G-protein signaling 2 (Rgs2). MiR-22 also reduces caspase 
activation by inhibiting pro-apoptotic protein expression (e.g. MAPK12/p38 and 
Tp53inp1) preventing neuronal apoptosis. These findings sustain the idea of enhanced 
miR-22 expression as therapeutic approach in HD (Jovicic, Zaldivar Jolissaint, Moser, 
Silva Santos, & Luthi-Carter, 2013). 
4.5.  Spinocerebellar ataxias  
Spinocerebellar ataxia is also a PolyQ disease characterized by 
neurodegeneration of the cerebellum, brain stem and spinocerebellar tracts. To date 30 
subtypes of SCAs have been identified (Orr, 2012). SCA patients have several 
movement disorders, such as, myoclonus, dystonia, chorea, parkinsonism and early 
tremor that depend on SCA subtypes (van Gaalen, Giunti, & van de Warrenburg, 2011). 
A set of miRNAs are selectively expressed in the human brain tissues, it is expected that 
miRNAs contribute to neuronal aging. Recently, Persengiev et al. (2011) discovered 
that miR-144 downregulates the expression of ataxin 1 (ATXN1), the disease-causing 
gene of SCA type 1 (Persengiev, Kondova, Otting, Koeppen, & Bontrop, 2011). This 
finding suggest miR-144 is a novel therapeutic target to slow down polyQ-induced 
neurodegeneration caused by mutant ATXN1.     
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5.  microRNAs and autoimmune diseases 
miRNAs play an important role in the regulation of innate and adaptive immune 
response, as even, in the immune cell development. Therefore, defective miRNA 
regulation in immune function has serious consequences, namely, immune cell cancers, 
loss of tolerance and development of autoimmunity, impaired adaptive immunity, 
inflammatory autoimmune disorders and dysregulation of antibody production (Pauley, 
Cha, & Chan, 2009). Various studies have revealed potential roles for miRNA 
regulation in autoimmune diseases, such as, psoriasis, rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE).  
5.1.  Psoriasis 
Psoriasis is an immune-mediated inflammatory disease that results from a 
complex interaction between genetic, immunological and environmental factors. This 
chronic disease affects the skin and joints and has a prevalence of 2-3% worldwide 
(Perera, Di Meglio, & Nestle, 2012). The epidermis of psoriasis patients is scaly and 
thick. The scales are a consequence of rapid maturation of keratinocytes and retention of 
nuclei in the stratum corneum (parakeratosis), whereas, the epidermal thickness occurs 
because the mitotic rate of the keratinocytes is augmented (acanthosis) (O. Nestle, H. 
Kaplan, & Barker, 2009). 
The miRNA expression profile in psoriasis is different when compared with 
miRNA expression profile in healthy skin. The miR-125b is downregulated in psoriatic 
lesional skin, however, its target, Fibroblast growth factor receptor 2 (FGFR2) 
expressed in keratinocytes is upregulated in psoriatic epidermis. Xu et al. (2011) have 
demonstrated that miR-125b inhibits keratinocytes proliferation and foments terminal 
differentiation through downregulation of FGFR2. This discovery suggests miR-125b as 
a possible target for psoriasis therapeutic management (Xu et al., 2011). 
Another fascinating study suggests a role of miRNAs in psoriasis. The dermal 
extracellular matrix in psoriatic skin has a degraded architecture as a result of epidermal 
proliferation into the dermis by matrix metalloproteases (MMP). Zibert et al. (2010) 
have found that miR-221 and miR-222 negatively regulate the metalloproteinase 
inhibitor 3 (TIMP3) in keratinocytes and thereby contributes to psoriasis pathogenesis  
(Zibert et al., 2010). 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
38 
5.2.  Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease of unknown cause 
characterized by synovitis and synovial hyperplasia (enlargement), autoantibody-
positive for rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA), 
cartilage degradation and bone erosion (McInnes & Schett, 2011). Several studies have 
implicated specific miRNAs in the pathophysiology of RA, namely, miR-146a and 
miR-23b. 
miR-146a is upregulated in CD4+ T cells of RA patients and has a positive 
correlation with TNF-α, a critical mediator of the inflammatory pathway in the 
rheumatoid joints. This miRNA negatively regulates Fas-associated factor 1 (FAF1) and 
suppresses T cell apoptosis. Therefore, increased miR-146a expression may be 
implicated in maintaining inflammation in RA. This discovery affords a promising 
novel therapeutic target in RA (J. Li et al., 2010). 
Abnormal inflammatory responses, like elevated expression of proinflammatory 
cytokines in RA (e.g. TNF-α, IL-1β and IL-17), boosts chronic inflammation and tissue 
damage in autoimmune diseases. miR-23b is downregulated in RA patients, once, the 
cytokine IL-17 downregulates miR-23b expression in human fibroblast- like 
synoviocytes. On the other hand, miR-23b robustly restrains inflammation by 
decreasing activation of the NFκB pathway and inflammatory cytokine expression, such 
as, TNF-α, IL-1β and IL-17. These outcomes suggest miR-23b may be a new target for 
therapeutic intervention of inflammatory diseases (S. Zhu et al., 2012). 
5.3.  Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune connective 
tissue disease characterized by a global loss of self- tolerance with production of 
pathogenic autoantibodies against nucleic acids and their binding proteins. Anomalous 
innate immune responses (e.g. release of inflammatory cytokines and autoreactive T and 
B cells) leads to production of autoantibodies and tissue injury (Choi, Kim, & Craft, 
2012). 
Qin et al. (2013) showed that miR-29b expression levels in CD4+ T cells from 
SLE patients are upregulated as compared with healthy patients. This miRNA 
negatively regulates the zinc finger transcription factor sp1 in T cells and by that way 
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indirectly downregulates DNA methyltransferase 1 (DNMT1) expression. DNMT1 
downregulation leads to overexpression of autoimmune-related methylation-sensitive 
genes (e.g. CD11 and CD70) and by this means DNA hypomethylation in lupus CD4+ T 
cells. DNA hypomethylation triggers the onset and progression of SLE. The therapeutic 
use of miR-29b inhibitors to reverse the hypomethylation status could be a potential 
strategy for the treatment of SLE (Qin et al., 2013).   
Another study hypothesized that abnormal expression of miRNAs in T cells may 
contribute to the pathogenesis of SLE. Lu et al. (2013) established that miR-145 is 
underexpressed in SLE T cells, whereas, miR-224 is overexpressed in SLE T cells. 
miR-145 directly targets the signal transducer and activator of transcription-1 (STAT1) 
and miR-224 directly targets the apoptosis inhibitory protein 5 (API5) 3’UTR mRNA. 
Increased expression of STAT1 in SLE T cells contributes to autoimmunity and lupus 
nephritis, whilst, decreased expression of API5 facilitates cell apoptosis which is 
consistent with T cell abnormalities in SLE. These findings suggest that miR-145 and 
miR-224 are potential novel therapeutic targets in patients with SLE (Lu et al., 2013).   
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6. microRNAs and cardiovascular diseases 
Expression levels of miRNAs is dysregulated in heart diseases, which suggests 
their involvement in cardiomyopathies, such as, arrhythmias, defects in ventricular  
septation, cardiac hypertrophy and myocyte hyperplasia (Callis & Wang, 2008). 
Energy homeostasis results from equilibrium between energy storage (e.g. food 
intake) and energy expenditure (e.g. physical activity). The dysregulation of this 
biologic mechanism is associated with obesity, diabetes mellitus, hypertension, 
hyperlipidemia and cardiovascular diseases. The mediator of RNA polymerase II 
transcription subunit 13 (MED13) regulates energy homeostasis and is downregulated 
by miR-208a, a heart-specific miRNA encoded by an intron of the MYH6 (also known 
as MyHC-α) gene [Figure 6]. The overexpression of MED13 or the inhibition of miR-
208a in mice leads to resistance to diet- induced obesity, improves systemic insulin 
sensitivity, resistance to metabolic syndrome and lower plasma lipid profile, whereas, 
deletion of MED13 contributes to diet- induced obesity and increases metabolic 
syndrome occurrence. This discover proposes that miR-208a inhibitors could represent 
an additional strategy in cardiovascular diseases therapy (Grueter et al., 2012; van Rooij 
& Olson, 2012). 
 
 
  
 
 
 
 
 
 
 
Figure 6 – Mult iple functions of miR-208a in the heart. (Retrieved from van Rooij & Olson, 2012). 
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7.  Strategies for microRNA-based therapies 
Therapeutic strategies based on modulation of miRNA expression and function 
can be divided in two main approaches: miRNA blocking (miRNA antagonists) and 
miRNA replacement (miRNA mimics) [Figure 7]. miRNA replacement consists of the 
delivery of miRNAs that are downregulated or deleted in tumours, whereas, miRNA 
blocking consists of the inhibition of miRNAs that are upregulated or overexpressed in 
tumours (Y. W. Kong, Ferland-McCollough, Jackson, & Bushell, 2012). 
Two major problems have delayed the miRNA-based therapies in vivo. The first 
hurdle is the low stability of RNA in vivo due to ribonuclease (RNase)-mediated 
degradation. The second difficulty is to guarantee tissue-specific delivery and sustained 
target inhibition. Once one single miRNA can regulate multiple mRNA targets is 
difficult to avoid off-target effects (Y. W. Kong et al., 2012). 
 
 
 
 
 
 
 
Figure 7 - Strategies for miRNA-based therapies. Blocking oncomiRs can be achieved by the use of 
antisense oligonucleotides, miRNA sponges, miR-mask and small-molecule inhib itors, whereas, 
replacement of tsmiRs could be reached by using synthetic miRNAs (miRNA mimics). ORF, open 
reading frame; UTR, untranslated region. (Adapted from Garzon, Marcucci, & Croce, 2010) . 
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7.1.  microRNA replacement therapy 
miRNA replacement is the reintroduction of a tumor-suppressor miRNA lost 
during carcinogenesis and the restoration of cellular programs commonly activated in 
normal cells that regulate oncogenic programs. For several years, the designation of a 
tumor suppressor was limited to protein-encoding genes but currently miRNA mimics 
also fit into the definition of tumor suppressor. miRNA mimics have a few advantages 
compared to gene therapy regarding the delivery of DNA plasmid or viral vector with 
protein-encoding genes. miRNAs mimics, contrary to the proteins, have low molecular 
weight, can be delivered systemically and are easily activated by crossing the cytoplasm 
layer of cancer cells (Bader, Brown, & Winkler, 2010). 
miRNA mimic technology involves the design of a synthetic RNA molecule 
with the ability to enter into the complex RISC and regulate the same target genes as the 
endogenous miRNA. To improve half- lives, specificity of RNA molecule and activity, 
several sugar and phosphate modifications can be integrated in miRNA mimic, such as, 
2´-O-methyl, 2´F, 2´NH2, 2´H, phosphorothioates and locked nucleic acids (LNAs) 
(Bader, Brown, Stoudemire, & Lammers, 2011).       
7.1.1. microRNA replacement therapy for liver cancer 
Hepatocellular carcinoma (HCC) is a highly prevalent disease, affecting more 
than half a million people globally. The major risk factors include hepatitis B virus 
(HBV) or HCV previous infection, alcoholic liver disease and nonalcoholic fatty liver 
disease (El-Serag, 2011). 
miR-26a has a high expression in normal hepatocytes, however, is reduced in 
HCC cells. This miRNA is a critical regulator of carcinogenesis and tumor progression 
because is responsible for the downregulation of cyclins D2 and E2 and induction of G1 
arrest. Kota et al. (2009) have demonstrated that systemic adeno-associated virus 
(AAV)-mediated delivery of miR-26a in HCC tumor-bearing mice suppresses HCC 
cells proliferation, increases tumor-specific apoptosis and reduces tumor progression 
(Kota et al., 2009). AAV is one of the most effective vectors for gene therapy, is a non-
pathogenic virus and has several serotypes with different tissue tropisms (Daya & 
Berns, 2008). For example, AAV type 8 exhibit preferential tropism for liver, whereas, 
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AAV type 9 display favored tropism for cardiac tissue and AAV type 2 for skeletal 
muscle (N.-C. Lee et al., 2012; Nathwani et al., 2011; Qi et al., 2010). 
7.1.2.  microRNA replacement therapy for lung cancer 
Lung cancer is the main cause of death cancer-related worldwide and 80% of 
lung cancers are classified as non-small cell lung carcinoma (NSCLC) (Farhat & 
Houhou, 2013). Both, miR-34a and let-7 are tumor suppressors that are downregulated 
in lung cancer. Trang and co-workers have verified that systemic delivery of miR-34a in 
Kras-activated mouse model of NSCLC using a neutral lipid emulsion (NLE) reduced 
60% of tumor area. This noteworthy discover supports the notion that miRNAs can 
regulate several targets because the proto-oncogene Kras is not directly repressed by 
miR-34a. Furthermore, let-7 and miR-34 have different tumor inhibition mechanisms: 
miR-34a reduces proliferation and increases apoptosis, whereas, let-7 only reduces 
proliferation. This suggests that combination therapy may enhance the therapeutic effect  
(Trang et al., 2011). 
7.2. microRNA blocking therapy 
7.2.1.  Anti-microRNA oligonucleotides 
Inhibition of miRNAs with antisense oligonucleotides have greatly contributed 
to the understanding of miRNAs biology. In particular, miRNA expression levels can be 
reduced by using anti-miRNA oligonucleotides (AMOs), also designated as antimiRs, 
that work through high affinity binding to the seed region of miRNA (Lennox & 
Behlke, 2011). If delivered systemically there are off-target effects and lack of tissue 
specificity. Thus, to overcome these problems chemical modifications are added to the 
oligonucleotides to improve biostability, binding affinity and potency (Torres, Fabani, 
Vigorito, & Gait, 2011). Modified RNAs can be added as backbone modifications (i.e. 
phosphorothioate; thiophosphororamidate; morpholino) and 2´-sugar ring modifications 
(i.e. 2´-O-Methyl; 2´-O-Methoxyethyl; 2´- fluoro; 2´,4´-Methylene (LNA)) (DeVos & 
Miller, 2013) [Figure 8].  
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Figure 8 – Design of chemically modified antimiR o ligonucleotides . (Retrieved from Stenvang, Petri, 
Lindow, Obad, & Kauppinen, 2012). 
 
The phosphorothioate backbone is the most extensively studied chemical 
modification that consists of replacement of one of the nonbridging oxygens by sulphur 
atom. Phosphorothioate oligonucleotides exhibit nuclease stability, easy synthesis, high 
solubility, significant antisense activity and are capable of activating RNase H activity 
(Dias & Stein, 2002). 2’-4’ LNA is a class of therapeutic agents in which the ribose 
sugar ring is locked by a oxymethylene bridge linking the 2´-O and 4´-C atoms (Veedu 
& Wengel, 2010). LNAs have notable characteristics, to be precise, high binding 
affinity regarding RNA or DNA, remarkable base pairing specificity, nuclease 
resistance, generally non-toxic and easily to manipulate (Veedu & Wengel, 2009).  
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Therapeutic silencing of disease-associated miRNAs using LNA-modified 
antimiRs oligonucleotides has been studied in lymphomas. A recent study demonstrated 
the role of an LNA-modified antimiR in the silencing of miRNAs associated to human 
diseases, such as, lymphomas. Waldenstrom´s macroglobulinemia (WM) is an rare 
indolent lymphoma, frequent in elderly and characterized by IgM monoclonal protein 
infiltration in BM (Buske & Leblond, 2013). miR-155 plays a critical role in the 
pathogenesis of B-cell malignancies and is overexpressed in B cells of transgenic mice. 
Zhang and colleagues have recently established that systemic delivery of tiny LNA 
antimiR-155 oligonucleotide in a mouse xenograft model of WM reduces tumor growth. 
This result emphasizes the value of tiny LNA antimiR therapy in hematologic 
malignancies (Y. Zhang et al., 2012). 
AntagomiRs are single-stranded RNA molecules containing cholesterol, 
conjugated via a 2´-O-methyl (2´-O-Me), complementary to the mature target miRNA 
and contain several phosphorothioate moieties. Phosphorothioate backbone linkages 
confers to the antagomiR, increased binding to plasma proteins and by that way 
decreases renal clearance, whereas, the cholesterol improves cellular uptake, in vivo 
stability and stimulates hepatic uptake (van Rooij & Olson, 2012).    
The first in vivo study showing that antagomiRs can effectively silence 
endogenous miRNAs was conducted by Krutzfeldt and colleagues [Figure 9]. They 
designed a cholesterol-conjugated and chemically modified RNA molecule, antagomiR-
122, which is selective for miR-122, a miRNA expressed at high levels in hepatocytes. 
Subsequently, the antagomiR-122 was administered to the mice by tail-vein injection 
and northern blot assay confirmed a clear decrease in endogenous miR-122 levels and 
marked decline in plasma cholesterol levels (about 44%) (Krützfeldt et al., 2005). The 
plasma cholesterol measurements showed reduced levels, once that, a round 300 genes 
were down-regulated as result of miRNA-122 silencing and at least 11 of these genes 
are involved in cholesterol biosynthesis (e.g. 3-hydroxy-3-methylglutaryl-CoA-
reductase) (Czech, 2006). This notable discover suggests miR-122 as a potential 
therapeutic target for the treatment of hypercholesterolemia and HCV infection because 
miR-122 is required for virus replication and assembly (Rottiers & Näär, 2012). 
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Figure 9 – Silencing miRNAs with antagomiRs . (Retrieved from Czech, 2006). 
 
Therapeutic silencing of miRNAs is a promising approach to suppress 
tumorigenesis. In vivo and in vitro silencing of miR-10b with antagomiR-10b notably 
decreases miR-10b levels and increases homeobox D10 (HOXD10) protein levels, 
leading to a decreased expression of Ras homolog gene family, member C (RhoC), a 
pro-metastatic gene. Systemic treatment of tumor-bearing mice with antagomiR-10b 
suppresses lung metastasis but does not reduce primary breast cancer growth [Figure 
10] (L. Ma et al., 2010). This remarkable study demonstrates that systemic 
administration of antagomiR-10b can efficiently target a tumor in vivo without major 
toxicity in mice. Therefore, prophylactic treatment of tumors that have not yet 
metastasized using miR-10b antagomiRs could be a novel therapy option in the near 
future (De Palma & Naldini, 2010).    
Figure 10 – Antagomir-10b treatment to prevent lung metastases  spread of breast cancer in mice. 
(Retrieved from De Palma & Naldin i, 2010). 
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7.2.2.  microRNA sponges  
miRNA sponges or target mimics are competitive inhibitors that contain several 
binding sites for a family of endogenous miRNAs sharing a common seed. They can be 
expressed from chromosomal transgene insertions if the intent is a partial miRNA 
inhibition or lentiviral and retroviral sponge vectors if the aim is long term miRNA 
inhibition (Ebert & Sharp, 2010). In vitro experiments demonstrated that miRNA 
sponges derepressed miRNA targets as robustly as chemically modified AMOs (Ebert, 
Neilson, & Sharp, 2007). 
Circular RNAs (circRNAs) firstly discovered in plants, results from a covalent 
coupling of the ends of a single RNA molecule. Nowadays, at least 2,000 human 
circRNAs have been identified (Memczak et al., 2013). A surprising recent study have 
demonstrated that a highly expressed circRNA in human and mouse brains operates as 
miR-7 sponge. It robustly suppresses miR-7, a central regulator of several cancers and 
Parkinson disease. Circular RNA sponge for miR-7 (ciRS-7) holds about 70 selectively 
conserved miR-7 target sites and is a promising candidate in neurological diseases and 
brain tumors therapies (Hansen et al., 2013). 
 
7.2.3.  microRNA-masking antisense oligonucleotide technology 
miRNA-masking antisense oligonucleotides (miR-masks) are single-stranded 2´-
O-methyl-modified antisense oligonucleotides complementary to the binding site of 
miRNA in 3´-UTR of mRNA target. Thus, the miR-mask prevents silencing without 
interfering with miRNAs in a gene-specific manner (Z. Wang, 2011). If the miR-mask 
sequence has perfect complementarity to the mRNA target, the duplexing will take 
place with high affinity compared with miR-mRNA target duplexing (Budhu, Ji, & 
Wang, 2010). 
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7.2.4.  Small-molecule inhibitors of microRNAs 
Modulation of misregulated miRNAs through small-molecules inhibitors of 
miRNAs is a promising approach in cancer therapy. Gumireddy et al. (2008) have 
discovered the first small-molecule inhibitor of the miRNA activity. They reported that 
azobenzene 2 specifically and efficiently inhibits miR-21 expression, an anti-apoptotic 
miRNA upregulated in several cancers (e.g. breast, ovarian and lung cancers)  
(Gumireddy et al., 2008). Another study identified two small molecules that suppress 
miRNA function and reverse tumorigenesis. Watashi et al. (2010) have identified two 
non-cytotoxic compounds, Polylysine (PLL) and Trypaflavine (TPF), which suppresses 
miRNA-RISC activity. In the miRNA biogenesis pathway, PLL inhibits dicing and TPF 
blocks loading. The researchers found that these compounds can reverse the 
tumorigenesis in cells that overexpress oncogenic miRNAs, such as, miR-93 and miR-
130b (Watashi, Yeung, Starost, Hosmane, & Jeang, 2010). 
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8. Routes to in vivo delivery of microRNAs 
Currently, there are several routes to delivery therapeutic miRNAs in vivo, such 
as, intratumoral, intramuscular, intravenous, intraperitoneal, intranasal and 
intracerebroventriculary [Figure 11]. 
  
 
 
 
 
 
 
 
 
 
 
Figure 11 – Routes to in vivo delivery of therapeutic miRNAs. (Adapted from Iorio & Croce, 2012; 
Nana-Sinkam & Croce, 2011). 
8.1.  Intratumoral 
Intratumoral injections have been exploited to delivery therapeutic miRs in 
many diseases, namely, renal cell carcinoma (RCC) and prostate cancer.  
RCC is a potentially curable disease representing 3% of all adult malignancies. 
The mainly risk factors are exposure to tobacco smoke, overweight and hypertension.  
Patients often complain of flank pain, hematuria and palpable abdominal mass. Some 
lines of evidence indicate that miRNAs may be involved in the pathogenesis of RCC 
(Al-Ali, Ress, Gerger, & Pichler, 2012; T. Cohen & J. McGovern, 2005).   
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A recent study demonstrated that miR-708 is a tumor suppressor in RCC and its 
expression is attenuated about 50-60% in RCC patients. Using an in vitro assay verified 
that replacement of miR-708 expression in RCC cell lines suppresses tumorigenicity 
through a notable increase in apoptosis. In addition to their in vitro data, they evaluated 
the therapeutic potential of a miR-708 mimic in vivo. They inoculated subcutaneously a 
RCC cell line into a mouse model and thirty days later a palpable tumor with 100-
150mm3 grow. Intratumoral delivery of miR-708 mimic every 3 days reduced 
significantly the tumor size [Figure 12]. This discovery reveals that miR-708 is a pro-
apoptotic miRNA in renal cancer and therefore is a striking target for prognosis and 
therapy of RCC (Saini et al., 2011). 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Representative images of mice from the two groups (miR-control and synthetic miR-708) 
before treatment (day 30) and after treatment (day 58). Intratumoral delivery of miR-708 leads to 
regression of tumors in a renal cancer xenograft mouse model. Subcutaneous tumors are indicated by 
arrows. (Retrieved from Sain i et al., 2011).  
 
Another exciting study documented the role of miR-34b in prostate cancer. This 
heterogeneous disease develops in the prostate gland and is the most prevalent non-
cutaneous neoplasm in males (Benedettini, Nguyen, & Loda, 2008). Majid et al. (2013) 
demonstrated that miR-34b is a tumor suppressor that is epigenetically silenced in 
prostate cancer through hypermethylation of CpG sites within CpG islands. The 
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antitumorigenic effect of miR-34b was checked in a prostate cancer xenograft mouse 
model. Intratumoral injection of a miR-34b mimic reduced the tumor volume (~12mm3) 
in established tumors, whereas, intratumoral injection of miR control (Cont-miR) 
increased the tumor volume (~136mm3) in established tumors [Figure 13]. 
Replacement of miR-34b in prostate cancer cells downregulates DNA methyltransferase 
(DNMT) and histone deacetylase (HDAC) inducing demethylation and active chromatin 
modifications. miR-34b also directly targets Akt proliferative pathway genes and 
epithelial-mesenchymal transition (EMT) markers generating antiproliferative effects 
and antimigratory/- invasive effects. These discoveries open a new horizon to targeting 
miR-34b and its epigenetic regulators for the treatment of prostate cancer (S. Majid et 
al., 2013). 
 
 
Figure 13 – Antitumorigenic effect of miR-34b in vivo. (Adapted from S. Majid et al., 2013). 
8.2.  Intramuscular 
Intramuscular injections of miRNAs have been studied in cardiac and skeletal 
muscle of mouse models to discover new therapeutic approaches for human diseases.  
Duchenne muscular dystrophy (DMD) is an incurable progressive disorder 
which results in muscular degeneration and accelerated death without intervention.  This 
disease is caused by a mutation in dystrophin gene that encodes to protein dystrophin, 
an essential protein for muscle membrane stability (Bushby et al., 2010; J. Fairclough, J. 
Wood, & E. Davies, 2013). A recent study has demonstrated that the muscle-specific 
miR-206 delays development of DMD in mice and boosts skeletal muscle regeneration 
in response to injury or disease. Therefore, the delivery of miR-206 mimic could be a 
therapeutic improvement for DMD management and other musculoskeletal disorders  
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(Ning Liu et al., 2012). Another study demonstrated that in vivo delivery of miRNAs 
facilitated recovery of skeletal muscle after injury. The muscle-specific miR-1, miR-133 
and miR-206 play an essential roles in regulation of muscle development. Nakasa et al. 
(2010) discovered that one single local injection of these miRNAs in rat tibialis anterior 
muscle accelerates muscle regeneration. This finding could represent a new approach in 
musculoskeletal disorders, namely in sports and traumatology medicine (Nakasa et al., 
2010).      
Myocardial infarction (MI), a major cause of death worldwide, is characterized 
by myocardial cell death owing prolonged ischemia (Thygesen et al., 2012). Hu et al. 
(2010) have discovered that miR-210 can rescue cardiac function in a murine model of 
MI. The researchers have showed that intramyocardial injections of miR-210 precursor 
through a nonviral minicircle vector improved left ventricular function after MI.  
Furthermore, histological analysis suggests that miR-210 promotes neovascularisation 
and inhibition of cellular apoptosis in the heart. This finding proposes that miR-210 is 
potentially useful in convalesce of human myocardial infarction (Hu et al., 2010).     
8.3.  Intraperitoneal 
miRNAs injected intraperitoneally have been studied in management of 
complicated diseases, such as, melanoma.  
Melanoma is a deadly cancer of the skin, killing one person per hour in the 
United States. In early-stage melanoma, a surgical excision can prevent disease 
development. Nevertheless, profound primary tumors or tumors that metastasize to 
regional lymph nodes usually spread to distant organs giving 6-9 months of survival 
time (Erdei & Torres, 2010). Therefore, novel therapeutic approaches against the 
metastatic melanoma, such as miRNA-based therapies, are crucial to improve the life 
span of these patients. miR-182 is up-regulated in human melanoma promoting invasion 
and migration in vitro, and boosts metastatic potential in vivo by directly suppressing 
Forkhead box O3 (FOXO3) and Microphthalmia-associated transcription factor-M 
(MITF-M) (Segura et al., 2009). A recent study showed that intraperitoneal injection of 
an anti-miR-182-modified oligonucleotide in a mouse model of melanoma liver 
metastasis reduced tumor burden and melanoma liver metastasis compared with control 
without significant toxicity [Figure 14] (Huynh et al., 2011). These findings suggest use 
of an anti-miR-182 as a hopeful strategy for metastatic melanoma treatment.  
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Figure 14 - Bioluminescent imaging at 4 weeks post intrasplenic injection of 1x10
4
 melanoma cells into 
mice. Mice were randomized into two groups, receiving either anti-miR-182 or negative control anti-miR 
administered by intraperitoneal in jection twice weekly. In vivo luciferase imaging showed that mice 
treated with anti-miR-182 had a lower burden of liver metastases compared with control. (Retrieved from 
Huynh et al., 2011). 
 
8.4.  Intravenous  
Intravenous injections of therapeutic miRNAs have been studied to target head 
and neck squamous cell carcinoma (HNSCC), obesity and type 2 diabetes.  
HNSCC is an aggressive cancer that appears in the oral cavity, oropharynx, 
larynx or hypopharynx. The main risk factors are tobacco smoking, alcohol 
consumption and high-risk types of human papillomavirus (HPV) (Leemans, Braakhuis, 
& Brakenhoff, 2011). miR-107 is downregulated and works as tumor suppressor in 
HNSCC. Piao et al. (2012) have verified that intravenous injection of cationic lipid 
nanoparticles delivering pre-miR-107 into a mouse model of HNSCC extensively 
retarded tumor growth (about 45%) when compared with nanoparticles delivering pre-
miRNA-control. Beside the role of miR-107 as a promising anticancer therapy for 
HNSCC, these results also reveal the eventual clinical application of cationic lipid-
based nanoparticle encapsulation as a carrier approach to deliver therapeutic miRNAs 
(Piao et al., 2012). 
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Some miRNAs that are deregulated in metabolic tissues from obese mice may 
eventually promote the development of obesity and type 2 diabetes. miR-802 is 
overexpressed in high fat diet (HFD)-fed mice, obese humans and mice homozygous for 
the diabetes db mutation of the leptin receptor (Leprdb/db). Hepatocyte nuclear factor 1 
homeobox b (Hnf1b) in a direct target of miR-802 and decreasing of Hnf1b in liver 
contributes to glucose intolerance, attenuates insulin sensitivity and stimulates hepatic 
gluconeogenesis. Kornfeld et al. (2013) have found that intravenous injection of a miR-
802 LNA oligonucleotide in HFD-fed mice results in lower serum insulin 
concentrations, glucose intolerance and insulin tolerance comparatively with control 
LNA oligonucleotide. These findings suggest that miR-802 inhibition could be used as 
therapeutic target in obesity and type 2 diabetes (Kornfeld et al., 2013). 
8.5.  Intranasal 
Intranasal delivery of miRNAs to the lungs of murine model of asthma has been 
studied. Asthma is a chronic inflammatory disorder of the airways affecting 300 million 
people worldwide. Type 2 CD4+ lymphocytes (Th2 cells) and their cytokines (e.g. IL-
13) play a key role in the pathogenesis of allergic asthma (Hansbro, Kaiko, & Foster, 
2011). In a recent study, Kumar et al. (2011) found that intranasal delivery of let-7 
mimic to the lungs of a murine model of asthma reduces IL-13 levels, an important 
cytokine responsible for inflammation and tissue remodelling in allergic asthma.  
Administration of let-7 mimic have also been conducted to attenuate asthma features, 
namely, airway hyperresponsiveness, airway inflammation and mucus metaplasia. 
These discoveries suggest that let-7 mimic therapy could be an attractive strategy to 
target inflammatory diseases like asthma (Kumar et al., 2011).  
8.6.  Intracerebroventricular 
Intracerebroventricular injection is a procedure to avoid the blood-brain barrier 
recently used to study neurological disorders related to miRs, such as, epilepsy. 
Epilepsy is a chronic neurological disorder, affecting millions of people worldwide, 
characterized by recurrent spontaneous seizures. The brain-specific miR-134 is 
upregulated in human epilepsy and negatively targets LIM kinase-1 (Limk1) mRNA, 
which plays a critical role in dendritic spine morphogenesis. A recent study 
demonstrated that intracerebroventriculary (i.c.v.) injection in mice with an LNA-
modified antagomiRs to miR-134 suppressed seizures and the hallmarks of epilepsy (i.e. 
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progressive neuron loss, gliosis and rearrangement of mossy fibers). This study is the 
first in vivo evidence that repression of a single mature miRNA, miR-134, can modify 
pathologic brain activity (Jimenez-Mateos et al., 2012). 
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9.  miRNAs and pharmacogenomics 
Many drugs are currently classified as “one size fits all” where a drug is 
developed for a specific disease non taking in account the individual’s genetic 
backgrounds. For this reason, approved drugs are occasionally removed after the 
postmarketing discovery because the occurrence of unexpected adverse effects (J. J. 
Chen, Lin, & Chen, 2013). 
Pharmacogenomics is the study of relations among individual patient genomes 
and transcriptomes and the efficacy and safety of a drug. The majority of 
pharmacogenomic research has focused on the analysis of single nucleotide 
polymorphisms (SNPs) and investigation of copy number variations (duplications and 
deletions) in human genome (Jakob Lewin Rukov & Shomron, 2011). 
Recent findings impute a new role for miRNAs in pharmacogenomics, the 
ability to control the efficacy of drugs. The expression of pharmacogenomic genes is 
crucial to drug function and miRNAs are key players in the regulation of these genes  (J. 
L. Rukov, Wilentzik, Jaffe, Vinther, & Shomron, 2013). Therefore, a miRNA affects 
the drug function through the regulation of genes that encode drug interacting proteins. 
Theoretically, the role of miRNAs in pharmacogenomics can be divided in three 
scenarios (Jakob Lewin Rukov & Shomron, 2011) [Figure 15]: 
Scenario 1 – In cells with normal miRNA transcription and processing, miRNA 
recognizes his mRNA target and downregulate genes that encode drug interacting 
proteins. In this scenario, the protein product binds and inhibits a drug at a low level; 
Scenario 2 – In cells with normal miRNA transcription and processing, miRNA 
fail to recognize his mRNA target due to SNP in the seed of the target sequence and 
genes that encode drug interacting proteins are protected from miRNA mediated 
downregulation. In this scenario, the protein product binds and inhibits a drug at a high 
level; 
Scenario 3 – In cells with disrupted miRNA transcription and processing, 
miRNA recognizes his mRNA target at a low level. In this scenario, the protein product 
binds and inhibits a drug at a medium level. 
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Figure 15 – The role of miRNA in pharmacogenomics . (Adapted from Jakob Lewin Rukov & Shomron, 
2011). 
 
Once miRNAs regulate about one-third of the human genome is plausible using 
them to predict drug response in individualized/personalized medicine (Mishra, 2012).  
A recent finding has demonstrated the role of miRNAs modulating drug efficacy 
in cancer cells. The human breast cancer resistance protein (BCRP) is responsible for 
pump out of cells various chemotherapeutic drugs (e.g. mitoxantrone), leading to a 
diminished concentration of drug within cancer cells and contributing to treatment 
failure. miR-487 directly binds to 3´UTR of BCRP mRNA and increases intracellular 
accumulation and antitumor effects of mitoxantrone in resistant breast cancer cells (M.-
T. Ma et al., 2013).  
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10.  Concluding remarks and future directions 
The quickly evolving field of miRNA world has raised more questions than 
answers. For example, miRNA biogenesis, function and stability are not yet fully 
understood. An improved comprehension of proteins that participate in miRNA 
biosynthesis pathways will undoubtedly trigger the development of miRNA-based 
therapies. Additional efforts need to be made to prevent off- target effects, refining 
chemical design and develop novel delivery methods (Garzon et al., 2010).  
In the last years considerable advances have been made to target specific 
miRNAs potentially involved in disease pathogenesis and prognosis. The studies 
described here illustrate the role of miRNAs as key players in cancers, 
neurodegenerative, autoimmune and cardiovascular diseases. Therefore, miRNAs are 
currently considered as “tiny players with big roles” in several biological processes  
(Kato & Slack, 2008; Lau et al., 2001).  
Two main difficulties have delayed miRNA drug developing, namely, the high 
false-positive rates in miRNA target prediction by in silico approaches and the required 
dose of miRNA drug to induce therapeutic effect may provoke unsafe off-target effects 
(Y. Li & Kowdley, 2012). The challenges for developing miRNA-based therapies 
include issues of delivery, potential off-target effects and safety. To overcome miRNA 
delivery hurdles, non-viral and viral strategies have been studied [Table 3] (Garzon et 
al., 2010). 
Table 3 – Limitations and advantages of direct microRNA-based therapeutic approaches . 
Strategy Limitations Advantages 
2´-O-Me phosphorothioate 
oligonucleotides 
Delivery;  
Short serum half-life;  
Poor cellular uptake;  
Off-target effects; 
Limited biological effects. 
Safe; 
Improved stability; 
Nuclease resistance; 
Increased binding affinity;  
2´-O-Me phosphorothioate 
oligonucleotides with cholesterol 
backbone 
Toxicity; 
Requires high doses. 
Good bioavailability. 
Locked nucleic acid 
Off-target effects; 
Potential dose toxicity effects; 
Safe; 
Good biodistribution; 
Effective. 
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miR-mask 
Limited scope (one target); 
Delivery. 
Effects are gene-specific;  
No off-target effects. 
miRNA sponge 
Delivery; 
Off-target effects. 
Able to silence a family of 
miRNAs. 
AAVs coding for miRNAs 
Potential dose toxicity effects; 
Off-target effects. 
Safe, efficient transduction; 
Long-term expression. 
AAVs, Adenovirus-associated vectors. (Adapted from Garzon et al., 2010). 
 
A variety of biotechnology companies are currently developing miRNA-based 
therapies for the treatment of cancer, cardiovascular, viral and metabolic diseases 
[Table 4]. Despite the vast attention around miRNA development therapy, only the 
anti-miR-122 (SPC3649) has entered to clinical phase.  
Table 4 – Companies developing miRNA-related technologies 
Company 
Therapeutic 
strategy 
Therapeutic area Clinical trial phase 
Santaris Pharma anti-miR-122 Chronic HCV infection Phase II 
Regulus 
therapeutics 
anti-miR-10b  
Suppression of lung metastasis 
from breast tumors  
Preclinical  
(mouse/rat) 
anti-miR-380-5p  Repression of neuroblastoma  
anti-miR-182 
Antagonizing liver metastasis 
from melanoma 
anti-miR-103/107 
Enhanced glucose homeostasis 
and insulin sensitivity 
anti-miR-21 
Interruption of migration/invasion 
of glioma and attenuation of 
cardiac dysfunction  
anti-miR-33a/b  Treatment of atherosclerosis 
Preclinical  
(non-human primates) 
Mirna 
therapeutics 
miR-34a mimic 
Treatment of several cancers  
Preclinical  
(non-human primates) 
Let-7 mimic Preclinical  
(mouse/rat) miR-16 mimic 
miRagen 
therapeutics 
anti-miR-15a Protects against cardiac ischemic 
injury  Preclinical  
(mouse/rat) 
anti-miR-195 
anti-miR-208 Treatment of chronic heart failure  
anti-miR-451 Polycythemia vera  
Adapted from (Hydbring & Badalian-Very, 2013). 
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In short, targeting disease-related miRNAs through miRNA-based therapies 
brings a new approach for several life-threatening disorders. The increasing number of 
miRNA publications and the vast number of pharmaceutical companies interested in 
miRNA drug developing suggests that in the near future new miRNA-based treatments 
can arise.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. References  
61 
11.  References 
Aalto, A. P., & Pasquinelli, A. E. (2012). Small non-coding RNAs mount a silent 
revolution in gene expression. Current Opinion in Cell Biology, 24(3), 333–340. 
doi:10.1016/j.ceb.2012.03.006 
Abe, M., & Bonini, N. M. (2013). MicroRNAs and neurodegeneration: role and impact. 
Trends in Cell Biology, 23(1), 30–36. doi:10.1016/j.tcb.2012.08.013 
Ahmad, J., Hasnain, S. E., Siddiqui, M. A., Ahamed, M., Musarrat, J., & Al-Khedhairy, 
A. A. (2013). MicroRNA in carcinogenesis & cancer diagnostics: A new 
paradigm. The Indian journal of medical research, 137(4), 680–694. 
Ahn, J., Segers, S., & Hayes, R. B. (2012). Periodontal disease, Porphyromonas 
gingivalis serum antibody levels and orodigestive cancer mortality. 
Carcinogenesis, 33(5), 1055–1058. 
Al-Ali, B. M., Ress, A. L., Gerger, A., & Pichler, M. (2012). MicroRNAs in renal cell 
carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. 
Anticancer Research, 32(9), 3727–3732. 
Amber, K., McLeod, M. P., & Nouri, K. (2013). The Merkel Cell Polyomavirus and Its 
Involvement in Merkel Cell Carcinoma. Dermatologic Surgery, 39(2), 232–238. 
doi:10.1111/dsu.12079 
Ambros, V. (1989). A hierarchy of regulatory genes controls a larva-to-adult 
developmental switch in C. elegans. Cell, 57(1), 49–57. 
Ameres, S. L., & Zamore, P. D. (2013). Diversifying microRNA sequence and function. 
Nature Reviews Molecular Cell Biology, 14(8), 475–488. doi:10.1038/nrm3611 
Amir, S., Ma, A.-H., Shi, X.-B., Xue, L., Kung, H.-J., & deVere White, R. W. (2013). 
Oncomir miR-125b Suppresses p14ARF to Modulate p53-Dependent and p53-
Independent Apoptosis in Prostate Cancer. PLoS ONE, 8(4), e61064. 
doi:10.1371/journal.pone.0061064 
Anaya-Ruiz, M., Bandala, C., & Pérez-Santos, J. (2013). miR-485 Acts as a Tumor 
Suppressor by Inhibiting Cell Growth and Migration in Breast Carcinoma T47D 
Cells. Asian Pacific Journal of Cancer Prevention, 14(6), 3757–3760. 
doi:10.7314/APJCP.2013.14.6.3757 
Avgeris, M., Stravodimos, K., Fragoulis, E. G., & Scorilas, A. (2013). The loss of the 
tumour-suppressor miR-145 results in the shorter disease-free survival of 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
62 
prostate cancer patients. British Journal of Cancer, 108(12), 2573–2581. 
doi:10.1038/bjc.2013.250 
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011). Developing therapeutic 
microRNAs for cancer. Gene therapy, 18(12), 1121–1126. 
doi:10.1038/gt.2011.79 
Bader, A. G., Brown, D., & Winkler, M. (2010). The Promise of MicroRNA 
Replacement Therapy. Cancer Research, 70(18), 7027–7030. doi:10.1158/0008-
5472.CAN-10-2010 
Bae, H. J., Noh, J. H., Kim, J. K., Eun, J. W., Jung, K. H., Kim, M. G., … Nam, S. W. 
(2013). MicroRNA-29c functions as a tumor suppressor by direct targeting 
oncogenic SIRT1 in hepatocellular carcinoma. Oncogene, 1–11. 
doi:10.1038/onc.2013.216 
Bala, S., Tilahun, Y., Taha, O., Alao, H., Kodys, K., Catalano, D., & Szabo, G. (2012). 
Increased microRNA-155 expression in the serum and peripheral monocytes in 
chronic HCV infection. Journal of translational medicine, 10(1), 151. 
doi:10.1186/1479-5876-10-151 
Beezhold, K. J., Castranova, V., & Chen, F. (2010). Review Microprocessor of 
microRNAs: regulation and potential for therapeutic intervention. Molecular 
Cancer, 9(134), 1–9. doi:10.1186/1476-4598-9-134 
Benedettini, E., Nguyen, P., & Loda, M. (2008). The pathogenesis of prostate cancer: 
from molecular to metabolic alterations. Diagnostic Histopathology, 14(5), 195–
201. 
Blechacz, B., Komuta, M., Roskams, T., & Gores, G. J. (2011). Clinical diagnosis and 
staging of cholangiocarcinoma. Nature reviews. Gastroenterology & 
hepatology, 8(9), 512–22. doi:10.1038/nrgastro.2011.131 
Bronevetsky, Y., & Ansel, K. M. (2013). Regulation of miRNA biogenesis and turnover 
in the immune system. Immunological Reviews, 253(1), 304–316. 
doi:10.1111/imr.12059 
Budhu, A., Ji, J., & Wang, X. (2010). The clinical potential of microRNAs. Journal of 
hematology & oncology, 3(1), 1–7. doi:10.1186/1756-8722-3-37 
Burlone, M. E., & Budkowska, A. (2009). Hepatitis C virus cell entry: role of 
lipoproteins and cellular receptors. The Journal of general virology, 90(Pt 5), 
1055–70. doi:10.1099/vir.0.008300-0 
11. References  
63 
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … 
Pandya, S. (2010). Diagnosis and management of Duchenne muscular 
dystrophy, part 1: diagnosis, and pharmacological and psychosocial 
management. The Lancet Neurology, 9(1), 77–93. doi:10.1016/S1474- 
4422(09)70272-8 
Buske, C., & Leblond, V. (2013). How to manage Waldenstrom’s macroglobulinemia. 
Leukemia, 27(4), 762–772. doi:10.1038/leu.2013.36 
Callis, T. E., & Wang, D.-Z. (2008). Taking microRNAs to heart. Trends in Molecular 
Medicine, 14(6), 254–260. doi:10.1016/j.molmed.2008.03.006 
Carbone, A., Cesarman, E., Spina, M., Gloghini, A., & Schulz, T. F. (2009). HIV-
associated lymphomas and gamma-herpesviruses. Blood, 113(6), 1213–24. 
doi:10.1182/blood-2008-09-180315 
Chen, B., Li, H., Zeng, X., Yang, P., Liu, X., Zhao, X., & Liang, S. (2012). Roles of 
microRNA on cancer cell metabolism. Journal of translational medicine, 10(1), 
228. doi:10.1186/1479-5876-10-228 
Chen, J. J., Lin, W.-J., & Chen, H.-C. (2013). Pharmacogenomic biomarkers for 
personalized medicine. Pharmacogenomics, 14(8), 969–980. 
doi:10.2217/pgs.13.75 
Cheung, G., Sahai, A., Billia, M., Dasgupta, P., & Khan, M. S. (2013). Recent advances 
in the diagnosis and treatment of bladder cancer. BMC medicine, 11(1), 13. 
doi:10.1186/1741-7015-11-13 
Cho, H. J., Liu, G., Jin, S. M., Parisiadou, L., Xie, C., Yu, J., … Cai, H. (2012). 
MicroRNA-205 regulates the expression of Parkinson’s disease-related leucine-
rich repeat kinase 2 protein. Human Molecular Genetics, 22(3), 608–620. 
doi:10.1093/hmg/dds470 
Choi, J., Kim, S. T., & Craft, J. (2012). The pathogenesis of systemic lupus 
erythematosus—an update. Current Opinion in Immunology, 24(6), 651–657. 
doi:10.1016/j.coi.2012.10.004 
Chou, J., Lin, J. H., Brenot, A., Kim, J., Provot, S., & Werb, Z. (2013). GATA3 
suppresses metastasis and modulates the tumour microenvironment by 
regulating microRNA-29b expression. Nature cell biology, 15(2), 201–13. 
doi:10.1038/ncb2672 
Citron, M. (2010). Alzheimer’s disease: strategies for disease modification. Nature 
Reviews Drug Discovery, 9(5), 387–398. doi:10.1038/nrd2896 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
64 
Corsi, A. K. (2006). A biochemist’s guide to Caenorhabditis elegans. Analytical 
biochemistry, 359(1), 1–17. doi:10.1016/j.ab.2006.07.033 
Costa, F. F. (2010). Non-coding RNAs: Meet thy masters. BioEssays, 32(7), 599–608. 
doi:10.1002/bies.200900112 
Creevey, L., Ryan, J., Harvey, H., Bray, I. M., Meehan, M., Khan, A. R., & Stallings, R. 
L. (2013). MicroRNA-497 increases apoptosis in MYCN amplified 
neuroblastoma cells by targeting the key cell cycle regulator WEE1. Molecular 
cancer, 12(1), 23. doi:10.1186/1476-4598-12-23 
Czech, M. P. (2006). MicroRNAs as therapeutic targets.  New England Journal of 
Medicine, 354(11), 1194–95. doi:10.1056/NEJMcibr060065 
Dai, D.-W., Lu, Q., Wang, L.-X., Zhao, W.-Y., Cao, Y.-Q., Li, Y.-N., … Yue, Z.-J. 
(2013). Decreased miR-106a inhibits glioma cell glucose uptake and 
proliferation by targeting SLC2A3 in GBM. BMC Cancer, 13(1), 478. 
doi:10.1186/1471-2407-13-478 
Dar, A. a, Majid, S., de Semir, D., Nosrati, M., Bezrookove, V., & Kashani-Sabet, M. 
(2011). miRNA-205 suppresses melanoma cell proliferation and induces 
senescence via regulation of E2F1 protein. The Journal of biological chemistry, 
286(19), 16606–14. doi:10.1074/jbc.M111.227611 
Darveau, R. P. (2010). Periodontitis: a polymicrobial disruption of host homeostasis. 
Nature reviews. Microbiology, 8(7), 481–90. doi:10.1038/nrmicro2337 
Davidson-Moncada, J., Papavasiliou, F. N., & Tam, W. (2010). MicroRNAs of the 
immune system: Roles in inflammation and cancer. Annals of the New York 
Academy of Sciences, 1183(1), 183–194. doi:10.1111/j.1749-6632.2009.05121.x 
Daya, S., & Berns, K. I. (2008). Gene Therapy Using Adeno-Associated Virus Vectors. 
Clinical Microbiology Reviews, 21(4), 583–593. doi:10.1128/CMR.00008-08 
De Palma, M., & Naldini, L. (2010). Antagonizing metastasis. Nature Biotechnology, 
28(4), 331–2. doi:10.1038/nbt0410-331 
De Planell-Saguer, M., & Rodicio, M. C. (2011). Analytical aspects of microRNA in 
diagnostics: A review. Analytica Chimica Acta, 699(2), 134–152. 
doi:10.1016/j.aca.2011.05.025 
DeVos, S. L., & Miller, T. M. (2013). Antisense Oligonucleotides: Treating 
Neurodegeneration at the Level of RNA. Neurotherapeutics, 10(3), 486–497. 
doi:10.1007/s13311-013-0194-5 
11. References  
65 
Dias, N., & Stein, C. A. (2002). Antisense oligonucleotides: basic concepts and 
mechanisms. Molecular cancer therapeutics, 1(5), 347–355. 
Dong, Y., Zhao, J., Wu, C.-W., Zhang, L., Liu, X., Kang, W., … Yu, J. (2013). Tumor 
Suppressor Functions of miR-133a in Colorectal Cancer. Molecular Cancer 
Research, 11(9), 1051–1060. doi:10.1158/1541-7786.MCR-13-0061 
Donglaima, Tao, X., Gao, F., Fan, C., & Wu, D. (2012). miR-224 functions as an onco-
miRNA in hepatocellular carcinoma cells by activating AKT signaling. 
Oncology Letters, 4(3), 483–488. doi:10.3892/ol.2012.742 
Doxakis, E. (2010). Post-transcriptional Regulation of -Synuclein Expression by mir-7 
and mir-153. Journal of Biological Chemistry, 285(17), 12726–12734. 
doi:10.1074/jbc.M109.086827 
Dumortier, O., Hinault, C., & Van Obberghen, E. (2013). MicroRNAs and Metabolism 
Crosstalk in Energy Homeostasis. Cell Metabolism, 18(3), 312–324. 
doi:10.1016/j.cmet.2013.06.004 
Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007). MicroRNA sponges: competitive 
inhibitors of small RNAs in mammalian cells. Nature Methods, 4(9), 721–726. 
doi:10.1038/nmeth1079 
Ebert, M. S., & Sharp, P. A. (2010). Emerging Roles for Natural MicroRNA Sponges. 
Current Biology, 20(19), R858–R861. doi:10.1016/j.cub.2010.08.052 
El-Serag, H. B. (2011). Hepatocellular Carcinoma. The New England Journal of 
Medicine, 365(12), 1118–27. doi:10.1056/NEJMra1001683 
Erdei, E., & Torres, S. M. (2010). A new understanding in the epidemiology of 
melanoma. Expert Review of Anticancer Therapy, 10(11), 1811–1823. 
doi:10.1586/era.10.170 
Fabian, M. R., & Sonenberg, N. (2012). The mechanics of miRNA-mediated gene 
silencing: a look under the hood of miRISC. Nature structural & molecular 
biology, 19(6), 586–93. doi:10.1038/nsmb.2296 
Faller, M., Toso, D., Matsunaga, M., Atanasov, I., Senturia, R., Chen, Y., … Guo, F. 
(2010). DGCR8 recognizes primary transcripts of microRNAs through highly 
cooperative binding and formation of higher-order structures. RNA (New York, 
N.Y.), 16(8), 1570–83. doi:10.1261/rna.2111310 
Farhat, F. S., & Houhou, W. (2013). Targeted therapies in non-small cell lung 
carcinoma: what have we achieved so far? Therapeutic Advances in Medical 
Oncology, 5(4), 249–270. doi:10.1177/ 1758834013492001 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
66 
Fei, X., Qi, M., Wu, B., Song, Y., Wang, Y., & Li, T. (2012). MicroRNA-195-5p 
suppresses glucose uptake and proliferation of human bladder cancer T24 cells 
by regulating GLUT3 expression. FEBS Letters, 586(4), 392–397. 
doi:10.1016/j.febslet.2012.01.006 
Feliciano, A., Castellvi, J., Artero-Castro, A., Leal, J. A., Romagosa, C., Hernández-
Losa, J., … LLeonart, M. E. (2013). miR-125b Acts as a Tumor Suppressor in 
Breast Tumorigenesis via Its Novel Direct Targets ENPEP, CK2-α, CCNJ, and 
MEGF9. PLoS ONE, 8(10), e76247. doi:10.1371/journal.pone.0076247 
Filatova, E. V., Alieva, A. K., Shadrina, M. I., & Slominsky, P. A. (2012). MicroRNAs: 
Possible role in pathogenesis of Parkinson’s disease. Biochemistry (Moscow), 
77(8), 813–819. doi:10.1134/S0006297912080020 
Fu, M., Li, S., Yu, T., Qian, L., Cao, R., Zhu, H., … Shi, R. (2013). Differential 
expression of miR-195 in esophageal squamous cell carcinoma and miR-195 
expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. 
FEBS Letters. doi:10.1016/j.febslet.2013.08.036 
Garzon, R., Marcucci, G., & Croce, C. M. (2010). Targeting microRNAs in cancer: 
rationale, strategies and challenges. Nature Reviews Drug Discovery, 9(10), 
775–789. doi:10.1038/nrd3179 
Giuliani, N., Storti, P., Bolzoni, M., Palma, B. D., & Bonomini, S. (2011). Angiogenesis 
and multiple myeloma. Cancer microenvironment : official journal of the 
International Cancer Microenvironment Society, 4(3), 325–37. 
doi:10.1007/s12307-011-0072-9 
Graves, P., & Zeng, Y. (2012). Biogenesis of mammalian microRNAs: a global view. 
Genomics, proteomics & bioinformatics, 10(5), 239–45. 
doi:10.1016/j.gpb.2012.06.004 
Griffiths-Jones, S. (2013, June). The miRBase Sequence Database -- Release 20. 
Retrieved September 19, 2013, from 
ftp://mirbase.org/pub/mirbase/CURRENT/README 
Grueter, C. E., van Rooij, E., Johnson, B. A., DeLeon, S. M., Sutherland, L. B., Qi, X., 
… Olson, E. N. (2012). A Cardiac MicroRNA Governs Systemic Energy 
Homeostasis by Regulation of MED13. Cell, 149(3), 671–683. 
doi:10.1016/j.cell.2012.03.029 
11. References  
67 
Gumireddy, K., Young, D. D., Xiong, X., Hogenesch, J. B., Huang, Q., & Deiters, A. 
(2008). Small-Molecule Inhibitors of MicroRNA miR-21 Function. Angewandte 
Chemie International Edition, 47(39), 7482–7484. doi:10.1002/anie.200801555 
Guo, L., & Lu, Z. (2010). The fate of miRNA* strand through evolutio nary analysis: 
implication for degradation as merely carrier strand or potential regulatory 
molecule? PloS one, 5(6), e11387. doi:10.1371/journal.pone.0011387 
Guo, Q. J., Mills, J. N., Bandurraga, S. G., Nogueira, L. M., Mason, N. J., Camp, E. R., 
… Findlay, V. J. (2013). MicroRNA-510 promotes cell and tumor growth by 
targeting peroxiredoxin1 in breast cancer. Breast Cancer Research, 15(4), R70. 
doi:10.1186/bcr3464 
Han, J., Lee, Y., Yeom, K.-H., Nam, J.-W., Heo, I., Rhee, J.-K., … Kim, V. N. (2006). 
Molecular basis for the recognition of primary microRNAs by the Drosha-
DGCR8 complex. Cell, 125(5), 887–901. doi:10.1016/j.cell.2006.03.043 
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70. 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646–74. doi:10.1016/j.cell.2011.02.013 
Hansbro, P. M., Kaiko, G. E., & Foster, P. S. (2011). Cytokine/anti-cytokine therapy - 
novel treatments for asthma? British Journal of Pharmacology, 163(1), 81–95. 
doi:10.1111/j.1476-5381.2011.01219.x 
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. 
K., & Kjems, J. (2013). Natural RNA circles function as efficient microRNA 
sponges. Nature, 495(7441), 384–388. doi:10.1038/nature11993 
Haramati, S., Chapnik, E., Sztainberg, Y., Eilam, R., Zwang, R., Gershoni, N., … 
Hornstein, E. (2010). miRNA malfunction causes spinal motor neuron disease. 
Proceedings of the National Academy of Sciences, 107(29), 13111–13116. 
doi:10.1073/pnas.1006151107 
Harata, K., Ishiguro, H., Kuwabara, Y., Kimura, M., Mitsui, A., Ogawa, R., … Fujii, Y. 
(2010). MicroRNA-34b has an oncogenic role in esophageal squamous cell 
carcinoma. Oncology Letters, 1(4), 685–689. doi:10.3892/ol_00000120 
Havens, M. A., Reich, A. A., Duelli, D. M., & Hastings, M. L. (2012). Biogenesis of 
mammalian microRNAs by a non-canonical processing pathway. Nucleic acids 
research, 40(10), 4626–40. doi:10.1093/nar/gks026 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
68 
He, J., Jing, Y., Li, W., Qian, X., Xu, Q., Li, F.-S., … Jiang, Y. (2013). Roles and 
mechanism of miR-199a and miR-125b in tumor angiogenesis. PloS one, 8(2), 
e56647. doi:10.1371/journal.pone.0056647 
Hirata, H., Ueno, K., Shahryari, V., Tanaka, Y., Tabatabai, Z. L., Hinoda, Y., & Dahiya, 
R. (2012). Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human 
Bladder Cancer. PLoS ONE, 7(11), e51056. doi:10.1371/journal.pone.0051056 
Holohan, K. N., Lahin, D. K., Schneider, B. P., Foroud, T., & Saykin, A. J. (2013). 
Functional microRNAs in Alzheimer’s disease and cancer: differential 
regulation of common mechanisms and pathways. Frontiers in Genetics, 3(323), 
1–16. doi:10.3389/fgene.2012.00323 
Hsu,  kai-W., Wang, A.-M., Ping, Y.-H., Huang, K.-H., Huang, T.-T., Lee, H.-C., … 
Yeh, T.-S. (2013). Downregulation of tumor suppressor MBP-1 by microRNA-
363 in gastric carcinogenesis. Carcinogenesis. doi:10.1093/carcin/bgt285 
Hu, S., Huang, M., Li, Z., Jia, F., Ghosh, Z., Lijkwan, M. A., … Wu, J. C. (2010). 
MicroRNA-210 as a Novel Therapy for Treatment of Ischemic Heart Disease. 
Circulation, 122(11_suppl_1), S124–S131. 
doi:10.1161/CIRCULATIONAHA.109.928424 
Huang, B.-S., Luo, Q.-Z., Han, Y., Li, X.-B., Cao, L.-J., & Wu, L.-X. (2013). 
microRNA-223 promotes the growth and invasion of glioblastoma cells by 
targeting tumor suppressor PAX6. Oncology Reports, 30(5), 2263–2269. 
doi:10.3892/or.2013.2683 
Huang, Q., Liu, L., Liu, C.-H., You, H., Shao, F., Xie, F., … Zhang, C.-H. (2013). 
MicroRNA-21 Regulates the Invasion and Metastasis in Cholangiocarcinoma 
and May Be a Potential Biomarker for Cancer Prognosis. Asian Pacific journal 
of cancer prevention : APJCP, 14(2), 829–34. 
Huang, Y., & Mucke, L. (2012). Alzheimer Mechanisms and Therapeutic Strategies. 
Cell, 148(6), 1204–1222. doi:10.1016/j.cell.2012.02.040 
Huynh, C., Segura, M. F., Gaziel-Sovran, A., Menendez, S., Darvishian, F., Chiriboga, 
L., … Zavadil, J. (2011). Efficient in vivo microRNA targeting of liver 
metastasis. Oncogene, 30(12), 1481–1488. doi:10.1038/onc.2010.523 
Hydbring, P., & Badalian-Very, G. (2013). Clinical applications of microRNAs. 
F1000Research, 2(136), 1–15. doi:10.12688/f1000research.2-136.v1 
11. References  
69 
Iorio, M. V., & Croce, C. M. (2012). MicroRNA dysregulation in cancer: diagnostics, 
monitoring and therapeutics. A comprehensive review. EMBO Molecular 
Medicine, 4(3), 143–159. doi:10.1002/emmm.201100209 
J. Fairclough, R., J. Wood, M., & E. Davies, K. (2013). Therapy for Duchenne muscular 
dystrophy: renewed optimism from genetic approaches. Nature Reviews 
Genetics, 14, 373–378. doi:10.1038/nrg3460 
Jimenez-Mateos, E. M., Engel, T., Merino-Serrais, P., McKiernan, R. C., Tanaka, K., 
Mouri, G., … Henshall, D. C. (2012). Silencing microRNA-134 produces 
neuroprotective and prolonged seizure-suppressive effects. Nature Medicine, 
18(7), 1087–1094. doi:10.1038/nm.2834 
Jovicic, A., Zaldivar Jolissaint, J. F., Moser, R., Silva Santos, M. de F., & Luthi-Carter, 
R. (2013). MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via 
General Anti-Apoptotic Effects and May also Target Specific Huntington’s 
Disease-Related Mechanisms. PLoS ONE, 8(1), e54222. 
doi:10.1371/journal.pone.0054222 
Junn, E., & Mouradian, M. M. (2010). MicroRNAs in neurodegenerative disorders. Cell 
Cycle, 9(9), 1717–1721. 
Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M., & Lang, A. E. (2013). α-
Synuclein oligomers and clinical implications for Parkinson disease. Annals of 
Neurology, 73(2), 155–169. doi:10.1002/ana.23746 
Kato, M., & Slack, F. J. (2008). microRNAs: small molecules with big roles -C. elegans 
to human cancer. Biology of the Cell, 100(2), 71–81. doi:10.1042/BC20070078 
Kaufman, D. S., Shipley, W. U., & Feldman, A. S. (2009). Bladder cancer. The Lancet, 
374(9685), 239–249. doi:10.1016/S0140- 6736(09)60491-8 
Ke, Y., Zhao, W., Xiong, J., & Cao, R. (2013). Downregulation of miR-16 promotes 
growth and motility by targeting HDGF in non-small cell lung cancer cells. 
FEBS Letters, 587(18), 3153–3157. doi:10.1016/j.febslet.2013.08.010 
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in epithelial 
ovarian cancer. Journal of experimental & clinical cancer research, 31(1), 14. 
doi:10.1186/1756-9966-31-14 
Kim, J. S., Yu, S. K., Lee, M. H., Park, M. G., Park, E., Kim, S. G., … Kim, D. K. 
(2013). MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, 
in human KB oral cancer cells. Molecules and cells, 35(1), 17–24. 
doi:10.1007/s10059-013-2154-7 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
70 
Kim, V. N., Han, J., & Siomi, C. (2009). Biogenesis of small RNAs in animals. Nature 
Reviews Molecular Cell Biology, 10(2), 126–139. doi:10.1038/nrm2632 
Kong, Y., Cui, H., Ramkumar, C., & Zhang, H. (2011). Regulation of senescence in 
cancer and aging. Journal of aging research, 1–15. doi:10.4061/2011/963172 
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012). 
microRNAs in cancer management. The lancet oncology, 13(6), e249–e258. 
doi:10.1016/S1470-2045(12)70073-6 
Kornfeld, J.-W., Baitzel, C., Könner, A. C., Nicholls, H. T., Vogt, M. C., Herrmanns, 
K., … Brüning, J. C. (2013). Obesity- induced overexpression of miR-802 
impairs glucose metabolism through silencing of Hnf1b. Nature, 494(7435), 
111–115. doi:10.1038/nature11793 
Kota, J., Chivukula, R. R., O’Donnell, K. A., Wentzel, E. A., Montgomery, C. L., 
Hwang, H.-W., … Mendell, J. T. (2009). Therapeutic microRNA Delivery 
Suppresses Tumorigenesis in a Murine Liver Cancer Model. Cell, 137(6), 1005–
1017. doi:10.1016/j.cell.2009.04.021 
Krobitsch, S., & Kazantsev, A. G. (2011). Huntington’s disease: From molecular basis 
to therapeutic advances. The International Journal of Biochemistry & Cell 
Biology, 43(1), 20–24. doi:10.1016/j.biocel.2010.10.014 
Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA 
biogenesis, function and decay. Nature Reviews Genetics, 11, 597–610. 
doi:10.1038/nrg2843 
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & 
Stoffel, M. (2005). Silencing of microRNAs in vivo with “antagomirs.” Nature, 
438(7068), 685–689. doi:10.1038/nature04303 
Kumar, M., Ahmad, T., Sharma, A., Mabalirajan, U., Kulshreshtha, A., Agrawal, A., & 
Ghosh, B. (2011). Let-7 microRNA–mediated regulation of IL-13 and allergic 
airway inflammation. Journal of Allergy and Clinical Immunology, 128(5), 
1077–1085. doi:10.1016/j.jaci.2011.04.034 
Ladewig, E., Okamura, K., Flynt, A. S., Westholm, J. O., & Lai, E. C. (2012). 
Discovery of hundreds of mirtrons in mouse and human small RNA data. 
Genome research, 22(9), 1634–45. doi:10.1101/gr.133553.111 
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001). Identification of 
novel genes coding for small expressed RNAs. Science (New York, N.Y.), 
294(5543), 853–8. doi:10.1126/science.1064921 
11. References  
71 
Lau, N. C., Lim, L. P., Weinstein, E. G., & Bartel, D. P. (2001). An abundant class of 
tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 
(New York, N.Y.), 294(5543), 858–62. doi:10.1126/science.1065062 
Laubach, J., Richardson, P., & Anderson, K. (2011). Multiple Myeloma. Annual Review 
of Medicine, 62(1), 249–264. doi:10.1146/annurev-med-070209-175325 
Lee, N.-C., Falk, D. J., Byrne, B. J., Conlon, T. J., Clement, N., Porvasnik, S., … 
Watson, R. (2012). An acidic oligopeptide displayed on AAV2 improves axial 
muscle tropism after systemic delivery. Genetic vaccines and therapy, 10(3), 1–
6. 
Lee, R. C., & Ambros, V. (2001). An extensive class of small RNAs in Caenorhabditis 
elegans. Science (New York, N.Y.), 294(5543), 862–4. 
doi:10.1126/science.1065329 
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene 
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 
843–54. 
Lee, S., Paulson, K. G., Murchison, E. P., Afanasiev, O. K., Alkan, C., Leonard, J. H., 
… Nghiem, P. (2011). Identification and validation of a novel mature 
microRNA encoded by the Merkel cell polyomavirus in human Merkel cell 
carcinomas. Journal of clinical virology : the official publication of the Pan 
American Society for Clinical Virology, 52(3), 272–5. 
doi:10.1016/j.jcv.2011.08.012 
Lee, S.-J., Lim, H.-S., Masliah, E., & Lee, H.-J. (2011). Protein aggregate spreading in 
neurodegenerative diseases: Problems and perspectives. Neuroscience Research, 
70(4), 339–348. doi:10.1016/j.neures.2011.05.008 
Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2011). The molecular 
biology of head and neck cancer. Nature Reviews Cancer, 11(1), 9–22. 
doi:10.1038/nrc2982 
Lennox, K. A., & Behlke, M. A. (2011). Chemical modification and design of anti-
miRNA oligonucleotides. Gene therapy, 18(12), 1111–1120. 
doi:10.1038/gt.2011.100 
Leong, J. W., Sullivan, R. P., & Fehniger, T. A. (2012). Natural Killer Cell Regulation 
by MicroRNAs in Health and Disease. Journal of Biomedicine and 
Biotechnology, 2012, 1–12. doi:10.1155/2012/632329 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
72 
Li, G., Zhang, Z. G., Tu, Y. Y., Jin, T. B., Liang, H. J., Cui, G. B., … Gao, G. D. 
(2013). Correlation of microrna-372 upregulation with poor prognosis in human 
glioma. Diagnostic Pathology, 8(1), 1–6. doi:10.1186/1746-1596-8-1 
Li, J., Wan, Y., Guo, Q., Zou, L., Zhang, J., Fang, Y., … Liu, H. (2010). Altered 
microRNA expression profile with miR-146a upregulation in CD4+ T cells from 
patients with rheumatoid arthritis. Arthritis research & therapy, 12(R81), 1–12. 
doi:10.1186/ar3006 
Li, Y., & Kowdley, K. V. (2012). MicroRNAs in Common Human Diseases. Genomics, 
Proteomics & Bioinformatics, 10(5), 246–253. doi:10.1016/j.gpb.2012.07.005 
Liang, C., Zhu, H., Xu, Y., Huang, L., Ma, C., Deng, W., … Qin, C. (2012). 
MicroRNA-153 negatively regulates the expression of amyloid precursor protein 
and amyloid precursor- like protein 2. Brain Research, 1455, 103–113. 
doi:10.1016/j.brainres.2011.10.051 
Lin, C.-W., Chang, Y.-L., Chang, Y.-C., Lin, J.-C., Chen, C.-C., Pan, S.-H., … Yang, 
P.-C. (2013). MicroRNA-135b promotes lung cancer metastasis by regulating 
multiple targets in the Hippo pathway and LZTS1. Nature Communications, 
4(1877), 1–14. doi:10.1038/ncomms2876 
Liu, J., Yang, B., & Ai, J. (2013). Advance in research of microRNA in Caenorhabditis 
elegans. Journal of cellular biochemistry, 114(5), 994–1000. 
doi:10.1002/jcb.24448 
Liu, L., Nie, J., Chen, L., Dong, G., Du, X., Wu, X., … Han, W. (2013). The Oncogenic 
Role of microRNA-130a/301a/454 in Human Colorectal Cancer via Targeting 
Smad4 Expression. PLoS ONE, 8(2), e55532. doi:10.1371/journal.pone.0055532 
Liu, Nan, Landreh, M., Cao, K., Abe, M., Hendriks, G.-J., Kennerdell, J. R., … Bonini, 
N. M. (2012). The microRNA miR-34 modulates ageing and neurodegeneration 
in Drosophila. Nature, 482(7386), 519–523. doi:10.1038/nature10810 
Liu, Ning, Williams, A. H., Maxeiner, J. M., Bezprozvannaya, S., Shelton, J. M., 
Richardson, J. A., … Olson, E. N. (2012). microRNA-206 promotes skeletal 
muscle regeneration and delays progression of Duchenne muscular dystrophy in 
mice. The Journal of Clinical Investigation, 122(6), 2054–2065. 
doi:10.1172/JCI62656 
Liu, X., Lv, X.-B., Wang, X.-P., Sang, Y., Xu, S., Hu, K., … Zeng, Y.-X. (2012). MiR-
138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by 
11. References  
73 
targeting the CCND1 oncogene. Cell Cycle, 11(13), 2495–2506. 
doi:10.4161/cc.20898 
Lu, M.-C., Lai, N.-S., Chen, H.-C., Yu, H.-C., Huang, K.-Y., Tung, C.-H., … Yu, C.-L. 
(2013). Decreased microRNA(miR)-145 and increased miR-224 expression in T 
cells from patients with systemic lupus erythematosus involved in lupus 
immunopathogenesis. Clinical & Experimental Immunology, 171(1), 91–99. 
doi:10.1111/j.1365-2249.2012.04676.x 
Luo, Q., Li, X., Gao, Y., Long, Y., Chen, L., Huang, Y., & Fang, L. (2013). MiRNA-
497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. 
Cancer Cell International, 13(1), 95. doi:10.1186/1475-2867-13-95 
Luo, Q., Li, X., Li, J., Kong, X., Zhang, J., Chen, L., … Fang, L. (2013). MiR-15a is 
underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. 
International Journal of Oncology, 43(4), 1212–1218. 
doi:10.3892/ijo.2013.2034 
Ma, D., Xiao, J., Li, Y., Diao, Y., Guo, Y., & Li, M. (2011). Feature importance 
analysis in guide strand identification of microRNAs. Computational biology 
and chemistry, 35(3), 131–6. doi:10.1016/j.compbiolchem.2011.04.009 
Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E. G., … Weinberg, 
R. A. (2010). Therapeutic silencing of miR-10b inhibits metastasis in a mouse 
mammary tumor model. Nature Biotechnology, 28(4), 341–347. 
doi:10.1038/nbt.1618 
Ma, M.-T., He, M., Wang, Y., Jiao, X.-Y., Zhao, L., Bai, X.-F., … Wei, M.-J. (2013). 
MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-
7/MX) to MX by targeting breast cancer resistance protein (BCRP/ ABCG2). 
Cancer Letters. doi:10.1016/j.canlet.2013.07.016 
Ma, Y., Yu, S., Zhao, W., Lu, Z., & Chen, J. (2010). miR-27a regulates the growth, 
colony formation and migration of pancreatic cancer cells by targeting Sprouty2. 
Cancer Letters, 298(2), 150–158. doi:10.1016/j.canlet.2010.06.012 
Majid, S., Dar, A. A., Saini, S., Shahryari, V., Arora, S., Zaman, M. S., … Dahiya, R. 
(2013). miRNA-34b Inhibits Prostate Cancer through Demethylation, Active 
Chromatin Modifications, and AKT Pathways. Clinical Cancer Research, 19(1), 
73–84. doi:10.1158/1078-0432.CCR-12-2952 
Majid, Shahana, Dar, A. A., Saini, S., Deng, G., Chang, I., Greene, K., … Yamamura, 
S. (2013). MicroRNA-23b Functions as a Tumor Suppressor by Regulating 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
74 
Zeb1 in Bladder Cancer. PLoS ONE, 8(7), e67686. 
doi:10.1371/journal.pone.0067686 
Margis, R., Margis, R., & Rieder, C. R. M. (2011). Identification of blood microRNAs 
associated to Parkinsońs disease. Journal of Biotechnology, 152(3), 96–101. 
doi:10.1016/j.jbiotec.2011.01.023 
Maris, J. M. (2010). Recent advances in neuroblastoma. The New England journal of 
medicine, 362(23), 2202–11. doi:10.1056/NEJMra0804577 
McInnes, I. B., & Schett, G. (2011). The pathogenesis of rheumatoid arthritis. New 
England Journal of Medicine, 365(23), 2205–2219. 
doi:10.1056/NEJMra1004965 
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., … Rajewsky, 
N. (2013). Circular RNAs are a large class of animal RNAs with regulatory 
potency. Nature, 495(7441), 333–338. doi:10.1038/nature11928 
Menghini, R., Casagrande, V., Cardellini, M., Martelli, E., Terrinoni, A., Amati, F., … 
Federici, M. (2009). MicroRNA 217 modulates endothelial cell senescence via 
silent information regulator 1. Circulation, 120(15), 1524–32. 
doi:10.1161/CIRCULATIONAHA.109.864629 
Mishra, P. J. (2012). The miRNA–drug resistance connection: a new era of personalized 
medicine using noncoding RNA begins. Pharmacogenomics, 13(12), 1321–
1324. doi:10.2217/pgs.12.121 
Mizoguchi, M., Guan, Y., Yoshimoto, K., Hata, N., Amano, T., Nakamizo, A., & 
Sasaki, T. (2013). Clinical implications of microRNAs in human glioblastoma. 
Frontiers in Oncology, 3(19), 1–6. doi:10.3389/fonc.2013.00019 
Müller, M., Kuiperij, H. B., Claassen, J. A., Küsters, B., & Verbeek, M. M. (2013). 
MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and 
cell- free cerebrospinal fluid. Neurobiology of Aging, 1–7. 
doi:10.1016/j.neurobiolaging.2013.07.005 
Nachmani, D., Stern-Ginossar, N., Sarid, R., & Mandelboim, O. (2009a). Diverse 
Herpesvirus MicroRNAs Target the Stress-Induced Immune Ligand MICB to 
Escape Recognition by Natural Killer Cells. Cell Host & Microbe, 5(4), 376–
385. doi:10.1016/j.chom.2009.03.003 
Nachmani, D., Stern-Ginossar, N., Sarid, R., & Mandelboim, O. (2009b). Diverse 
herpesvirus microRNAs target the stress- induced immune ligand MICB to 
11. References  
75 
escape recognition by natural killer cells. Cell host & microbe, 5(4), 376–85. 
doi:10.1016/j.chom.2009.03.003 
Nakasa, T., Ishikawa, M., Shi, M., Shibuya, H., Adachi, N., & Ochi, M. (2010). 
Acceleration of muscle regeneration by local injection of muscle-specific 
microRNAs in rat skeletal muscle injury model. Journal of Cellular and 
Molecular Medicine, 14(10), 2495–2505. doi:10.1111/j.1582-
4934.2009.00898.x 
Nana-Sinkam, S. P., & Croce, C. M. (2011). MicroRNAs as therapeutic targets in 
cancer. Translational Research, 157(4), 216–225. doi:10.1016/j.trsl.2011.01.013 
Nathwani, A. C., Tuddenham, E. G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, 
D. C., … Harrington, C. (2011). Adenovirus-associated virus vector–mediated 
gene transfer in hemophilia B. New England Journal of Medicine, 365(25), 
2357–2365. doi:10.1056/NEJMoa1108046 
Nohata, N., Hanazawa, T., Kinoshita, T., Okamoto, Y., & Seki, N. (2013). MicroRNAs 
function as tumor suppressors or oncogenes: Aberrant expression of microRNAs 
in head and neck squamous cell carcinoma. Auris Nasus Larynx, 40(2), 143–
149. doi:10.1016/j.anl.2012.07.001 
O. Nestle, F., H. Kaplan, D., & Barker, J. (2009). Psoriasis. The New England Journal 
of Medicine, 361(5), 496–509. doi:10.1056/NEJMra0804595 
Orr, H. T. (2012). The cell biology of disease: Cell biology of spinocerebellar ataxia.  
The Journal of Cell Biology, 197(2), 167–177. doi:10.1083/jcb.201105092 
Palumbo, A., & Anderson, K. (2011). Multiple myeloma. The New England journal of 
medicine, 364(11), 1046–60. doi:10.1056/NEJMra1011442 
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, 
B., … Ruvkun, G. (2000). Conservation of the sequence and temporal 
expression of let-7 heterochronic regulatory RNA. Nature, 408(6808), 86–9. 
doi:10.1038/35040556 
Pauley, K. M., Cha, S., & Chan, E. K. L. (2009). MicroRNA in autoimmunity and 
autoimmune diseases. Journal of Autoimmunity, 32(3-4), 189–194. 
doi:10.1016/j.jaut.2009.02.012 
Pécheur, E.-I. (2012). Lipoprotein Receptors and Lipid Enzymes in Hepatitis C Virus 
Entry and Early Steps of Infection. Scientifica, 1–11. doi:10.6064/2012/709853 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
76 
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012). Psoriasis. Annual Review of 
Pathology: Mechanisms of Disease, 7(1), 385–422. doi:10.1146/annurev-pathol-
011811-132448 
Persengiev, S., Kondova, I., Otting, N., Koeppen, A. H., & Bontrop, R. E. (2011). 
Genome-wide analysis of miRNA expression reveals a potential role for miR-
144 in brain aging and spinocerebellar ataxia pathogenesis. Neurobiology of 
Aging, 32(12), 2316.e17–2316.e27. doi:10.1016/j.neurobiolaging.2010.03.014 
Piao, L., Zhang, M., Datta, J., Xie, X., Su, T., Li, H., … Pan, Q. (2012). Lipid-based 
Nanoparticle Delivery of Pre-miR-107 Inhibits the Tumorigenicity of Head and 
Neck Squamous Cell Carcinoma. Molecular Therapy, 20(6), 1261–1269. 
doi:10.1038/mt.2012.67 
Qi, Y., Liu, X., Li, H., Shenoy, V., Li, Q., Hauswirth, W. W., … Katovich, M. J. 
(2010). Selective tropism of the recombinant adeno-associated virus 9 serotype 
for rat cardiac tissue. The Journal of Gene Medicine, 12(1), 22–34. 
doi:10.1002/jgm.1404 
Qin, H., Zhu, X., Liang, J., Wu, J., Yang, Y., Wang, S., … Xu, J. (2013). MicroRNA-
29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus 
erythematosus by indirectly targeting DNA methyltransferase 1. Journal of 
Dermatological Science, 69(1), 61–67. doi:10.1016/j.jdermsci.2012.10.011 
Rather, M. I., Nagashri, M. N., Swamy, S. S., Gopinath, K. S., & Kumar, A. (2013). 
Oncogenic MicroRNA-155 Down-regulates Tumor Suppressor CDC73 and 
Promotes Oral Squamous Cell Carcinoma Cell Proliferation. Journal of 
Biological Chemistry, 288(1), 608–618. doi:10.1074/jbc.M112.425736 
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli,  a E., Bettinger, J. C., Rougvie,  a 
E., … Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature, 403(6772), 901–6. 
doi:10.1038/35002607 
Reis, S., Pontes-Junior, J., Antunes, A., Dall’Oglio, M., Dip, N., Passerotti, C., … Leite, 
K. (2012). miR-21 may acts as an oncomir by targeting RECK, a matrix 
metalloproteinase regulator, in prostate cancer. BMC Urology, 12(14), 1–7. 
doi:10.1186/1471-2490-12-14 
Ren, J., Zhu, D., Liu, M., Sun, Y., & Tian, L. (2010). Downregulation of miR-21 
modulates Ras expression to promote apoptosis and suppress invasion of 
11. References  
77 
Laryngeal squamous cell carcinoma. European Journal of Cancer, 46(18), 
3409–3416. doi:10.1016/j.ejca.2010.07.047 
Robberecht, W., & Philips, T. (2013). The changing scene of amyotrophic lateral 
sclerosis. Nature Reviews Neuroscience, 14(4), 248–264. doi:10.1038/nrn3430 
Ross, C. A., & Tabrizi, S. J. (2011). Huntington’s disease: from molecular pathogenesis 
to clinical treatment. The Lancet Neurology, 10(1), 83–98. doi:10.1016/S1474-
4422(10)70245-3 
Rottiers, V., & Näär, A. M. (2012). MicroRNAs in metabolism and metabolic disorders. 
Nature Reviews Molecular Cell Biology, 13(4), 239–250. doi:10.1038/nrm3313 
Roush, S., & Slack, F. J. (2008). The let-7 family of microRNAs. Trends in cell biology, 
18(10), 505–16. doi:10.1016/j.tcb.2008.07.007 
Rukov, J. L., Wilentzik, R., Jaffe, I., Vinther, J., & Shomron, N. (2013). Pharmaco-miR: 
linking microRNAs and drug effects. Briefings in Bioinformatics. 
doi:10.1093/bib/bbs082 
Rukov, Jakob Lewin, & Shomron, N. (2011). MicroRNA pharmacogenomics: Post-
transcriptional regulation of drug response. Trends in Molecular Medicine, 
17(8), 412–423. doi:10.1016/j.molmed.2011.04.003 
Saini, S., Yamamura, S., Majid, S., Shahryari, V., Hirata, H., Tanaka, Y., & Dahiya, R. 
(2011). MicroRNA-708 Induces Apoptosis and Suppresses Tumorigenicity in 
Renal Cancer Cells. Cancer Research, 71(19), 6208–6219. doi:10.1158/0008-
5472.CAN-11-0073 
Segura, M. F., Hanniford, D., Menendez, S., Reavie, L., Zou, X., Alvarez-Diaz, S., … 
Bogunovic, D. (2009). Aberrant miR-182 expression promotes melanoma 
metastasis by repressing FOXO3 and microphthalmia-associated transcription 
factor. Proceedings of the National Academy of Sciences, 106(6), 1814–1819. 
doi:10.1073/pnas.0808263106 
Shao, Y., Qu, Y., Dang, S., Yao, B., & Ji, M. (2013). MiR-145 inhibits oral squamous 
cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer cell 
international, 13(51), 1–9. doi:10.1186/1475-2867-13-51 
Shiiba, M., Shinozuka, K., Saito, K., Fushimi, K., Kasamatsu, A., Ogawara, K., … 
Tanzawa, H. (2013). MicroRNA-125b regulates proliferation and radioresistance 
of oral squamous cell carcinoma. British journal of cancer, 108(9), 1817–21. 
doi:10.1038/bjc.2013.175 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
78 
Shirasaki, T., Honda, M., Shimakami, T., Horii, R., Yamashita, T., Sakai, Y., … 
Kaneko, S. (2013). MicroRNA-27a regulates lipid metabolism and inhibits 
hepatitis C virus replication in human hepatoma cells. Journal of virology, 
87(9), 5270–86. doi:10.1128/JVI.03022-12 
Sicard, F., Gayral, M., Lulka, H., Buscail, L., & Cordelier, P. (2013). Targeting miR-21 
for the Therapy of Pancreatic Cancer. Molecular Therapy, 21(5), 986–994. 
doi:10.1038/mt.2013.35 
Slack, F. J., Basson, M., Liu, Z., Ambros, V., Horvitz, H. R., & Ruvkun, G. (2000). The 
lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-
7 regulatory RNA and the LIN-29 transcription factor. Molecular cell, 5(4), 
659–69. 
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012). Inhibition of 
microRNA function by antimiR oligonucleotides. Silence, 3(1), 1–17. 
doi:10.1186/1758-907X-3-1 
Sun, C.-Y., She, X.-M., Qin, Y., Chu, Z.-B., Chen, L., Ai, L.-S., … Hu, Y. (2013). miR-
15a and miR-16 affect the angiogenesis of multiple myeloma by targeting 
VEGF. Carcinogenesis, 34(2), 426–35. doi:10.1093/carcin/bgs333 
Sun, D., Yu, F., Ma, Y., Zhao, R., Chen, X., Zhu, J., … Zhang, J. (2013). MicroRNA-31 
activates the RAS pathway and functions as an oncogenic MicroRNA in human 
colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). 
The Journal of Biological Chemistry, 288(13), 9508–9518. 
doi:10.1074/jbc.M112.367763 
T. Cohen, H., & J. McGovern, F. (2005). Renal-Cell Carcinoma. The New England 
Journal of Medicine, 353(23), 2477–90. 
Taft, R. J., Pang, K. C., Mercer, T. R., Dinger, M., & Mattick, J. S. (2010). Non-coding 
RNAs: regulators of disease. The Journal of Pathology, 220(2), 126–139. 
doi:10.1002/path.2638 
Takahashi, T., Saikawa, Y., & Kitagawa, Y. (2013). Gastric Cancer: Current Status of 
Diagnosis and Treatment. Cancers, 5(1), 48–63. doi:10.3390/cancers5010048 
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., & White, H. 
D. (2012). Third universal definition of myocardial infarction. Nature Reviews 
Cardiology, 9(11), 620–633. doi:10.1038/nrcardio.2012.122 
Torres, A. G., Fabani, M. M., Vigorito, E., & Gait, M. J. (2011). MicroRNA fate upon 
targeting with anti-miRNA oligonucleotides as revealed by an improved 
11. References  
79 
Northern-blot-based method for miRNA detection. RNA, 17(5), 933–943. 
doi:10.1261/rna.2533811 
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., … Slack, F. J. 
(2011). Systemic Delivery of Tumor Suppressor microRNA Mimics Using a 
Neutral Lipid Emulsion Inhibits Lung Tumors in Mice. Molecular Therapy, 
19(6), 1116–1122. doi:10.1038/mt.2011.48 
Van Gaalen, J., Giunti, P., & van de Warrenburg, B. P. (2011). Movement disorders in 
spinocerebellar ataxias. Movement Disorders, 26(5), 792–800. 
doi:10.1002/mds.23584 
Van Rooij, E., & Olson, E. N. (2012). MicroRNA therapeutics for cardiovascular 
disease: opportunities and obstacles. Nature Reviews Drug Discovery, 11(11), 
860–872. doi:10.1038/nrd3864 
Veedu, R. N., & Wengel, J. (2009). Locked nucleic acid as a novel class of therapeutic 
agents. RNA biology, 6(3), 321–323. 
Veedu, R. N., & Wengel, J. (2010). Locked nucleic acids: promising nucleic acid 
analogs for therapeutic applications. Chemistry & biodiversity, 7(3), 536–542. 
doi:10.1002/cbdv.200900343 
Wang, Y., Huang, J.-W., Li, M., Cavenee, W. K., Mitchell, P. S., Zhou, X., … 
Taniguchi, T. (2011). MicroRNA-138 modulates DNA damage response by 
repressing histone H2AX expression. Molecular cancer research : MCR, 9(8), 
1100–11. doi:10.1158/1541-7786.MCR-11-0007 
Wang, Z. (2011). The Principles of MiRNA-Masking Antisense Oligonucleotides 
Technology. In W. Wu (Ed.), MicroRNA and Cancer: Methods and Protocols  
(Vol. 676, pp. 43–49). Totowa, NJ: Humana Press. Retrieved from 
http://link.springer.com/10.1007/978-1-60761-863-8_3 
Watashi, K., Yeung, M. L., Starost, M. F., Hosmane, R. S., & Jeang, K.-T. (2010). 
Identification of Small Molecules That Suppress MicroRNA Function and 
Reverse Tumorigenesis. Journal of Biological Chemistry, 285(32), 24707–
24716. doi:10.1074/jbc.M109.062976 
Westholm, J. O., & Lai, E. C. (2011). Mirtrons: microRNA biogenesis via splicing. 
Biochimie, 93(11), 1897–904. doi:10.1016/j.biochi.2011.06.017 
Williams, A. H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J. L., … Olson, E. 
N. (2009). MicroRNA-206 Delays ALS Progression and Promotes Regeneration 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
80 
of Neuromuscular Synapses in Mice. Science, 326(5959), 1549–1554. 
doi:10.1126/science.1181046 
Wong, R. S. Y. (2011). Apoptosis in cancer: from pathogenesis to treatment. Journal of 
experimental & clinical cancer research : CR, 30(1), 87. doi:10.1186/1756-
9966-30-87 
Wright, M. W., & Bruford, E. A. (2011). Naming “junk”: human non-protein coding 
RNA (ncRNA) gene nomenclature. Human genomics, 5(2), 90–98. 
Wu, C.-D., Kuo, Y.-S., Wu, H.-C., & Lin, C.-T. (2011). MicroRNA-1 induces apoptosis 
by targeting prothymosin alpha in nasopharyngeal carcinoma cells. Journal of 
biomedical science, 18(1), 80. doi:10.1186/1423-0127-18-80 
Wu, C.-W., Dong, Y.-J., Liang, Q.-Y., He, X.-Q., Ng, S. S. M., Chan, F. K. L., … Yu, 
J. (2013). MicroRNA-18a attenuates DNA damage repair through suppressing 
the expression of ataxia telangiectasia mutated in colorectal cancer. PloS one, 
8(2), e57036. doi:10.1371/journal.pone.0057036 
Xiao, F., Zhang, W., Chen, L., Chen, F., Xie, H., Xing, C., … Zhou, L. (2013). 
MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and 
E2F3 in hepatocellular carcinoma. Journal of Translational Medicine, 11(195), 
1–10. doi:10.1186/1479-5876-11-195 
Xie, Y., Tobin, L. a, Camps, J., Wangsa, D., Yang, J., Rao, M., … Kwong, K. F. (2013). 
MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells. 
Oncogene, 32(19), 2442–51. doi:10.1038/onc.2012.258 
Xie, Y.-F., Shu, R., Jiang, S.-Y., Liu, D.-L., Ni, J., & Zhang, X.-L. (2013a). 
MicroRNA-146 inhibits pro- inflammatory cytokine secretion through IL-1 
receptor-associated kinase 1 in human gingival fibroblasts. Journal of 
Inflammation, 10(1), 20. doi:10.1186/1476-9255-10-20 
Xie, Y.-F., Shu, R., Jiang, S.-Y., Liu, D.-L., Ni, J., & Zhang, X.-L. (2013b). 
MicroRNA-146 inhibits pro- inflammatory cytokine secretion through IL-1 
receptor-associated kinase 1 in human gingival fibroblasts. Journal of 
inflammation (London, England), 10(1), 20. doi:10.1186/1476-9255-10-20 
Xu, N., Brodin, P., Wei, T., Meisgen, F., Eidsmo, L., Nagy, N., … Pivarcsi, A. (2011). 
MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte 
proliferation by targeting FGFR2. Journal of Investigative Dermatology, 131, 
1521–1529. doi:10.1038/jid.2011.55 
11. References  
81 
Yang, T.-S., Yang, X.-H., Wang, X.-D., Wang, Y.-L., Zhou, B., & Song, Z.-S. (2013). 
MiR-214 regulate gastric cancer cell proliferation, migration and invasion by 
targeting PTEN. Cancer cell international, 13(1), 68. doi:10.1186/1475-2867-
13-68 
Yu, X., Zhen, Y., Yang, H., Wang, H., Zhou, Y., Wang, E., … Fang, W. (2013). Loss of 
connective tissue growth factor as an unfavorable prognosis factor activates 
miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in 
nasopharyngeal carcinoma. Cell Death and Disease, 4(5), e634. 
doi:10.1038/cddis.2013.153 
Yungang, W., Xiaoyu, L., Pang, T., Wenming, L., & Pan, X. (2013). miR-370 targeted 
FoxM1 functions as a tumor suppressor in laryngeal squamous cell carcinoma 
(LSCC). Biomedicine & Pharmacotherapy. doi:10.1016/j.biopha.2013.08.008 
Zhang, J., Lu, Y., Yue, X., Li, H., Luo, X., Wang, Y., … Wan, J. (2013). MiR-124 
Suppresses Growth of Human Colorectal Cancer by Inhibiting STAT3. PLoS 
ONE, 8(8), e70300. doi:10.1371/journal.pone.0070300 
Zhang, Xiangyang, Nie, Y., Du, Y., Cao, J., Shen, B., & Li, Y. (2012). MicroRNA-181a 
promotes gastric cancer by negatively regulating tumor suppressor KLF6. 
Tumor Biology, 33(5), 1589–1597. doi:10.1007/s13277-012-0414-3 
Zhang, Xiaoxiao, & Zeng, Y. (2010). Regulation of mammalian microRNA expression. 
Journal of cardiovascular translational research, 3(3), 197–203. 
doi:10.1007/s12265-010-9166-x 
Zhang, Y., Roccaro, A. M., Rombaoa, C., Flores, L., Obad, S., Fernandes, S. M., … 
Ghobrial, I. M. (2012). LNA-mediated anti-miR-155 silencing in low-grade B-
cell lymphomas. Blood, 120(8), 1678–1686. doi:10.1182/blood-2012-02-410647 
Zhao, G., Wang, B., Liu, Y., Zhang, J., Deng, S., Qin, Q., … Wang, C. (2013). 
MicroRNA-141, downregulated in pancreatic cancer, inhibited the cell 
proliferation and invasion by directly targeting MAP4K4. Molecular cancer 
therapeutics. doi:10.1158/1535-7163.MCT-13-0296 
Zhao, W.-G., Yu, S.-N., Lu, Z.-H., Ma, Y.-H., Gu, Y.-M., & Chen, J. (2010). The miR-
217 microRNA functions as a potential tumor suppressor in pancreatic ductal 
adenocarcinoma by targeting KRAS. Carcinogenesis, 31(10), 1726–1733. 
doi:10.1093/carcin/bgq160 
MicroRNAs in pathology and as therapeutic targets in gene therapy 
82 
Zhao, Y., Li, C., Wang, M., Su, L., Qu, Y., Li, J., … Zhu, Z. (2013). Decrease of miR-
202-3p Expression, a Novel Tumor Suppressor, in Gastric Cancer. PLoS ONE, 
8(7), e69756. doi:10.1371/journal.pone.0069756 
Zhou, C., Liu, G., Wang, L., Lu, Y., Yuan, L., Zheng, L., … Li, X. (2013). MiR-339-5p 
Regulates the Growth, Colony Formation and Metastasis of Colorectal Cancer 
Cells by Targeting PRL-1. PLoS ONE, 8(5), e63142. 
doi:10.1371/journal.pone.0063142 
Zhu, H.-C., Wang, L.-M., Wang, M., Song, B., Tan, S., Teng, J.-F., & Duan, D.-X. 
(2012). MicroRNA-195 downregulates Alzheimer’s disease amyloid-β 
production by targeting BACE1. Brain Research Bulletin, 88(6), 596–601. 
doi:10.1016/j.brainresbull.2012.05.018 
Zhu, S., Pan, W., Song, X., Liu, Y., Shao, X., Tang, Y., … Qian, Y. (2012). The 
microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by 
targeting TAB2, TAB3 and IKK-α. Nature Medicine, 18(7), 1077–1086. 
doi:10.1038/nm.2815 
Zibert, J. R., Løvendorf, M. B., Litman, T., Olsen, J., Kaczkowski, B., & Skov, L. 
(2010). MicroRNAs and potential target interactions in psoriasis. Journal of 
Dermatological Science, 58(3), 177–185. doi:10.1016/j.jdermsci.2010.03.004 
 
 
